Pubertal trajectory and the management of menstruation in females with Rett syndrome and Down syndrome by Knight, Olivia Annelies
Edith Cowan University 
Research Online 
Theses : Honours Theses 
2010 
Pubertal trajectory and the management of menstruation in 
females with Rett syndrome and Down syndrome 
Olivia Annelies Knight 
Edith Cowan University 
Follow this and additional works at: https://ro.ecu.edu.au/theses_hons 
 Part of the Occupational Therapy Commons 
Recommended Citation 
Knight, O. A. (2010). Pubertal trajectory and the management of menstruation in females with Rett 
syndrome and Down syndrome. https://ro.ecu.edu.au/theses_hons/1363 
This Thesis is posted at Research Online. 
https://ro.ecu.edu.au/theses_hons/1363 
Edith Cowan University 
  
Copyright Warning 
  
 
  
You may print or download ONE copy of this document for the purpose 
of your own research or study. 
 
The University does not authorize you to copy, communicate or 
otherwise make available electronically to any other person any 
copyright material contained on this site. 
 
You are reminded of the following: 
 
 Copyright owners are entitled to take legal action against persons 
who infringe their copyright. 
 
 A reproduction of material that is protected by copyright may be a 
copyright infringement. Where the reproduction of such material is 
done without attribution of authorship, with false attribution of 
authorship or the authorship is treated in a derogatory manner, 
this may be a breach of the author’s moral rights contained in Part 
IX of the Copyright Act 1968 (Cth). 
 
 Courts have the power to impose a wide range of civil and criminal 
sanctions for infringement of copyright, infringement of moral 
rights and other offences under the Copyright Act 1968 (Cth). 
Higher penalties may apply, and higher damages may be awarded, 
for offences and infringements involving the conversion of material 
into digital or electronic form.
Pubertal Trajectory and the Management 
of Menstruation in Females with Rett 
Syndrome and Down Syndrome. 
Olivia Annelies Knight 
A report submitted in Partial Fulfilment of the Requirements for the Award of 
Bachelor of Occupational Therapy, Honours, Faculty of Computing, Health and 
Science, Edith Cowan University 
Submitted (October 2010) 
USE OF THESIS 
 
 
The Use of Thesis statement is not included in this version of the thesis. 
COPYRIGHT AND ACCESS DECLARATION 
1 certify that this thesis does not, to the best of my knowledge and belief 
(i) Incorporate without acknowledgment any material previously submitted for a 
,- degree or diploma in any institution of higher degree or diploma in any institution 
of higher education; 
(ii) Contain any material previously published or written by another person except 
where due reference is made in the text of this thesis; or 
(iii) Contain any defamatory material. 
(iv) Contain any data that has not been collected in a manner consistent with ethics 
approval. 
The Ethics Committee may refer any incidents involving requests for ethics approval after 
data collection to the relevant Faculty for action. 
Signed ... 
oate ...... I f .. /v 7.: ~~~((, ....... .. 
Puberty I 
Pubertal Trajectory and the Management of 
Menstruation in Females with Rett Syndrome and 
Down Syndrome. 
Olivia Annelies Knight 
A report submitted in Partial Fulfilment ofthe Requirements for the Award of 
Bachelor of Occupational Therapy, Honours, Faculty of Computing, Health and 
Science, Edith Cowan University 
Submitted (October 2010) 
I declare that this written assignment is my 
Own work and does not include 
(I) material from published sources 
used without proper acknowledgement, or 
(II) Material copied from the work of other students 
Signature 
Date I (1/lo Z /!-ol I 
Puberty II 
Declaration 
I certify that this thesis does not incorporate, without acknowledgement, any material 
previously submitted for a degree or diploma in any institution of higher education and 
that, to the best of my knowledge and belief, it does not contain any material previously 
published or written by another person except where due reference is made in the text 
9 
Signature ________________________________________________________ __ 
Date ___ ~--'-ij-'--/c_u_2___.:_/_2_0_/_l ________ _ 
Puberty III 
Acknowledgements 
This review and research project was supported through collaboration between the 
Telethon Institute for Child Health Research and Edith Cowan University. In particular, I 
acknowledge my supervisors for their ongoing energy, assistance and contributions. 
Without their assistance this research would not have been possible. 
Dr Helen Leonard, (Senior Researcher at Telethon Institute for Child Health Research) 
for her ongoing support, advice and assistance and her expertise knowledge 
Dr Sonya Girdler, (Senior Lecturer at Edith Cowan University) for her steady guidance 
and supervision. 
Ms Jenny Bourke, (Senior Researcher at TICHR), for her assistance and her expertise 
knowledge into Down syndrome 
Ms Ami Bebbington (Data Statistician at TICHR) for all her assistance in all aspects of 
Data management and analysis. 
Dr Aris Siafarikas for his advice and expertise into Endocrinology 
I would also like to acknowledge fellow researchers Stephanie Fehr and Kitty Rose Foley 
at the TICH for assisting me and providing support throughout the year 
Puberty IV 
Table of Contents 
List of Figures .................................................................................................................... VI 
List of Tables .................................................................................................................. VIII 
Abbreviations .................................................................................................................... .IX 
LITERATURE REVIEW: Pubertal Trajectory and the Management of Menstruation in 
Females ,with Rett Syndrome and Down Syndrome. 
Abstract. ............................................................................................................................... 2 
Introduction .......................................................................................................................... 3 
Methods ................................................................................................................................ 4 
Results 
Normative Population ..................................................................................................... 5 
Rett syndrome .................................................................................................................. 6 
Down syndrome ............................................................................................................ . 13 
Menstruation ................................................................................................................ . 16 
Managing Menstruation ..................................................................................... , ......... . 19 
Discussion .......................................................................................................................... 25 
Conclusion ......................................................................................................................... 25 
References .......................................................................................................................... 29 
Appendix 
Table 1 ........................................................................................................................... 43 
Journal Guidelines ............................................................................................................. 50 
Puberty V 
RESEARCH REPORT: Pubertal Trajectory and the Management of Menstruation in 
Females with Rett Syndrome and Down Syndrome. 
Abstract. ............................................................................................................................. 54 
Introduction ........................................................................................................................ 55 
Methods 
Rett syndrome ............................................................................................................... . 57 
Down syndrome ............................................................................................................. 60 
Results 
Rett syndrome ................................................................................................................ 62 
Down syndrome ...................................................................................................... ....... 65 
Discussion .......................................................................................................................... 6 8 
Figures ................................................................................................................................ 79 
Tables ................................................................................................................................. 88 
Appendix 
Australian Rett syndrome Survey 2006 .............. ........................................................ .1 02 
Down syndrome NOW survey 2004 ............................................................................ 1 05 
Journal Guidelines ........................................................................................................... lOS 
Puberty VI 
LIST OF FIGURES 
Figure 1 (MECP2 gene) .................................................................................................... 8 
Figure 2 (Tanner pubic hair stages) .... , ........................................................................... 55 
Figure 3 (Tanner Breast development stages) ............................ ., .................................... 55 
Figure 4 (Survival estimates of Tanners stage two) ......................................................... 80 
Figure 5,(Tanners stage two and BMI) ............................................................................ 80 
Figure 6 (Tanners stage two and mutation) ...................................................................... 81 
Figure 7 (Survival estimates ofMenarche) ....................................................................... 81 
Figure 8 (Menarche and BMI) .......................................................................................... 82 
Figure 9_ (Menarche and Mutation) ................................................................................... 82 
Figure 10 (Survival estimates between Tanners stage two and menarche) ...................... 83 
Figure 11 (Tanners stage two-menarche and BMI) .......................................................... 83 
Figure 12 (Tanners stage two-menarche and mutation) ................................................... 84 
Figure 13 (Tanners stage two-menarche scatter plot) ..................................................... 84 
Figure 14 (Menstrual suppressants in Rett syndrome) ..................................................... 85 
Figure 15 (Pubertal issues in Rett syndrome) ................................................................... 85 
Figure 16 (Survival estimates of first sign of puberty, Down syndrome) ........................ 86 
Figure 17 (Survival estimates of Menarche, Down syndrome) ........................................ 86 
Figure 18 (Menstrual suppressants in Down syndrome) .................................................. 87 
Figure 19 (Pubertal issues in Down syndrome) ................................................................ 87 
Puberty VII 
LIST OF TABLES 
Table 1 (Summary of Key Literature) .......................................................... .43 
Table 2 (Life table and Tanners stage two) ...................................................... 89 
Table 3 (Genotype and Tanner stage two) ....................................................... 89 
Table 4 (Life table and Menarche) ................................................................ 92 
Table 5 (,Genotype and Tanner stage two) ........................................................ 94 
Table 6 (Life table and Tanners stage two-Menarche) ......................................... 95 
Table 7 (Genotype and Tanner stage two) ....................................................... 96 
Table 8 (Rett syndrome and menstrual suppressants) ......................................... 97 
Table 10 (Rett syndrome and issues experienced in puberty) ................................. 97 
Table 11 (Life table and Down syndrome Puberty) ........................................... 98 
Table 12 (Life table and Down syndrome Menarche) ........................................ 99 
Table 12 (Down syndrome and Menstrual suppressants) .................................... 100 
Table 14 (Down syndrome and the issues experienced in puberty) ........................ 1 00 
Pube1iy VIII 
ABBREVIATIONS 
ARSD- Australian Rett Syndrome Database; A population-based database 
established in 1993. 
BDR- Birth Defects Registry 
DHEA- Dehydroepiandrosterone 
DHEAS- Dehydroepiandrosterone Sulphate 
3 Beta HSD- 3 beta- hydroxysteriod dehydrogenase 
GnRH- Gonadotrophin-releasing hormone 
LH- Luteinizing Hormone 
FSH- Follicle Stimulating Hormone 
GH- Growth Hormone 
MECP2- Methyl CpG binding protein 2 
TD- Thyroid Dysfunction 
T4- Thyroxine 
TSH- Thyroid Stimulating Hormone 
IRTSH- Isolated Raised Thyroid Stimulating Hormone 
TFT- Thyroid Function Test 
DMPA- Depot Medroxypreogesterone Acetate 
OCP- Oral Contraceptives Pill 
MIRENA- Levongestrel Intrauterine System or LNG-IUS 
BMD- Bone Mineral Density 
Puberty 1 
Literature Review 
Pubertal Trajectory and the management of 
· Menstruation in Females with Rett 
Syndrome and Down Syndrome 
Olivia Annelies I<night 
Puberty 2 
Pubertal Trajectory and the Management of Menstruation in Females with Rett 
syndrome and Down syndrome 
Abstract 
Background: Puberty is a challenging transition for all young women and particularly so 
for those with an intellectual disability. Individuals with an intellectual disability often 
experience both cognitive and physical impairment and a wide range of comorbidities. 
This review explores research into the pubertal trajectory and the management of 
menstruation in two syndromes within intellectual disability. Rett syndrome which is a 
severe neurodevelopmental disorder and Down syndrome which is a chromosomal birth 
disorder. 
Aim: The purpose of this review was to identify research exploring pube1ial trajectory 
and menstrual management in females with Rett syndrome and Down syndrome and to 
identify aspects of these syndromes which may impact puberty for these individuals. 
Methods: Databases MEDLINE, CINHAL, Proquest Health and Medical Complete and 
lSI web of Science/ Knowledge were electronically searched to identify relevant miicles 
from earliest electronic record to 2010. A priori criteria for inclusion of studies were 
applied first to abstracts and to full texts. Studies were included if they explored 
reproductive, endocrinological, musculoskeletal systems or pube1iy in females with Rett 
syndrome, Down syndrome and Intellectual disability. 
Results: Electronic database searches identified 97 relevant miicles with predominately 
cross sectional methodology. Literature identified abnormalities in bone growth and 
endocrinothapies in Rett syndrome and a high prevalence of thyroid dysfunction in Down 
syndrome both of which have been documented to affect puberty. Epilepsy was highly 
prevalent in both syndromes suggesting high incidences of catamenial epilepsy. 
Menstrual management was affected by a wide variety of factors with no perfect solution 
presenting. 
Conclusion: Literature documented growth retardation, early pubarche and abnormal 
hormone secretion in Rett syndrome suggesting an underlying endocrine dysfunction. 
Puberty in Down syndrome is likely to be delayed due to high occurrence of thyroid 
dysfunction particularly hypothyroidism. Managing menstruation within this population 
is an area of controversy as many options negatively impact health however reduce 
distress and discomfmi for the individual and the carer. There is a paucity of research into 
this field and a large propmiion of studies carried out have weak methodological quality 
and use small sample sizes reducing the generalisability. 
Author (Olivia Knight) 
Supervisor (Dr Helen Leonard 1, Dr Sonya Girdler1' 2, 
Ms Jenny Bourke1, Ms Ami Bebbington1 
And Dr Aris Siafarikas3) 
Telethon Institute for Child Health Research (1); 
Edith Cowan University (2); 
Princes Margaret Hospital for Children (3) 
Submitted (October 2010) 
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PUBERTAL TRAJECTORY AND THE MANAGEMENT OF MENSTRUATION 
IN FEMALES WITH RETT SYNDROME AND DOWN SYNDROME 
Introduction 
Puberty describes the transition period between childhood and adulthood in which the 
ability to reproduce is attained (Terasawa & Fernandez, 2001). In females it is a complex 
biological process manifested by the development of secondary sex characteristics, 
,-
accelerated growth, development of genitalia and menarche. The onset and tempo of 
puberty is regulated by two independently occurring physiological processes: adrenarche 
and gonadarche (Ellis, 2004; Plant & Barker-Gibb, 2004). Adrenarche occurs when levels 
of dehydroepiandrosterone (DHEA) and dehydroepiandrosterone sulphate (DHEAS) 
begin to_ rise due to reduced levels of 3 beta- hydroxysteriod dehydrogenase (3 Beta 
HSD). This usually occurs between five and seven years of age and plateaus at 
approximately 20 years of age (Ellis, 2004). Gonadarche occurs between nine and ten 
years of age and is due to the reactivation of gonadotrophin-releasing hormone (GnRH) 
resulting in the release of luteinizing hormone (LH) and follicle stimulating hormone 
(FSH). Together these processes are responsible for the development of ovaries, 
secondary sex characteristics, an increase in production of sex hormones, widening of 
hips, menarche and fe1iility (Ellis, 2004). 
This review aims to identify pubertal trajectory and the management of menstruation in 
two intellectual disability syndromes through exploring research into the reproductive, 
endocrine and musculoskeletal systems in Rett syndrome and Down syndrome. Rett 
syndrome is a severe neurodevelopmental disorder representing a severe intellectual 
disability (Mount, Hastings, Reily, Cass, & Charman, 2001) and Down syndrome is a 
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clu·omosomal birth disorder representing a milder intellectual disability which is still 
often associated with a moderate level of intellectual handicap (Bower et al., 2009; 
Petterson et al., 2005). Due to the paucity of research into puberty in females with Rett 
syndrome and Down syndrome literature pe1iaining to pube1iy in females with an 
intellectual disability has been included. 
Puberty is a challenging transition for all young women and particularly so for those with 
an intellectual disability. In addition to cognitive impairment individuals with an 
intellectual disability often experience physical impairment and a wide range of 
comorbidities. 
Methods 
Electronic searches of four databases were used to identify and locate relevant studies for 
inclusion. Each database was searched from its earliest electronic records (MEDLINE 
from 1966, CINHAL from 1982, Proquest Health and Medical Complete and lSI web of 
Science/ knowledge from 1985) to July 2010. Key search terms were Down syndrome, 
Rett syndrome, intellectual disability, puberty, pubertal trajectory, pubarche, thelarche, 
menarche, menstruation, contraception, epilepsy, bone dysmorphologies imd 
endocrinopathies. All search terms were truncated, exploded and adjusted to match 
specific database requirements. Searches were limited to English language and peer 
reviewed articles. The reference lists of all relevant articles were manually searched to 
ensure all relevant literature was included. Conference proceedings were not searched 
however searches ofthe Australian New Zealand Gynaecology Journal and Journals of 
Intellectual disability were included. 
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A priori criteria for inclusion of studies were applied first to abstracts and to full texts in 
the instance of abstracts not providing sufficient information. Studies were included if 
they explored reproductive, endocrine, musculoskeletal systems or pube1ty in females 
with Rett syndrome, Down syndrome and intellectual disability. Sample sizes and 
methodology were not limited due to the paucity of research in this field. The level of 
evidence of miicles was based on the National Health and Medical Research Council 
guidelines (National Health and Medical Research Council, 1999). The data extracted 
,. 
from literature included, the objectives, design, method, participants, pmticipant 
recruitment method, results and the conclusions. 
Results 
Due to the broad selection criteria electronic searches of databases identified 
approximately 1000 articles, once initial exclusion was carried out (n=26) CINHAL, 
(n=33) MEDLINE, (n=129) Proquest Health and Medical Complete and (n= 46) lSI Web 
of Knowledge/ Science 96 articles were selected. Descriptions of included studies are 
presented in table 1. The literature in this field will be presented in five themes: pubetiy 
in the normative population, Rett syndrome, Down syndrome, menstrual issues, and 
methods of menstrual management. 
Normative Population 
Research conducted in Europe pmiicularly Norway, Denmark and Finland has identified 
that over the last two centuries the average age of pubetial onset has significantly reduced 
from 16 to 17 years of age in the 1800's to 13 years by the mid 1900's, (Kaplowitz, 
2008), with the rate of decrease stabilising over the last 50 years (Denzer et al., 2007; 
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Onland-Moret et al., 2005). This decrease has been largely attributed to the 
improvements in nutrition, hygiene, health status and socioeconomic status (Anderson, 
Dallal, & Must, 2003). This phenomenon has resulted in a resurgence of interest within 
this field. Comparisons between studies are limited by factors such as varying 
methodologies and differing markers of pubertal onset. In 2001 Thomas, Renaud, 
Benefice, De Meeus and Guegan reviewed studies ofthe average age of pubertal onset in 
67 countries. Findings from this review revealed that the youngest average age of 
pube1ial onset at 12 years of age was reported in 1982 in the Congo and 1984 in Greece 
(Pentoz-Deponte & Grefen-Peters, 1984). The oldest average age of pubertal onset was 
16.1 years and was reported from Senegal (Simondon, Simon, & Simondon, 1997). 
Australian research, conducted by Morabia and Costanza in 1998 revealed the average 
age of pube1ial onset in Australia was 13 years of age, similar to the findings in Britain, 
Chile, Belgium, Cuba, Sardinia, Indonesia and Norway (F. Thomas, Renaud, Benefice, 
De Meeus, & Guegan, 2001 ). Although findings from this review are important in 
enabling a description of international variation in relation to average age of pube1ial 
onset, comparison between countries was impacted by variations in methodologies used, 
the cross-sectional nature ofthe majority of the research, population sampling methods, 
and the nearly thiliy year span of the research. 
Rett syndrome 
Rett syndrome is a severe neurodevelopmental disorder resulting in cognitive and 
physical impairment and almost exclusively affecting females (Mount, et al., 2001). Rett 
syndrome occurs in 1 :9000 and is a leading cause of severe intellectual disability in 
Australia (Laurvick et al., 2006). Rett syndrome was first described in 1966 by Dr 
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Andreas Rett, however it was not until 1983 when Hagberg and colleagues reported on a 
group of females with neurodevelopmental disorders characterised by decelerated head 
growth and severe mental retardation that Rett syndrome was described in an English 
publication (Hagberg, Aicardi, Dias, & Ramos, 1983). 
Due to the absence of a biological marker an international working group developed 
clinical criteria that all need to be met for a diagnosis of classical Rett syndrome 
(Hagberg, Guitieres, Hanefield, Rett, & Wilson, 1985). However it was recognised that 
the phenotypic spectrum extended beyond these criteria which resulted in the 
introduction of the term "atypical Rett syndrome" (Hagberg, Hanefeld, Percy, & 
Skjeldal, 2002). 
Stages o[Rett syndrome 
The natural progression ofRett syndrome follows a series of stages (Hagberg, 2002). The 
first stage is commonly known as early onset stagnation and is described as a period of 
slowing development. Stage two, developmental regression, is described as an obvious 
loss of functional abilities. The third stage, the pseudeostationary stage, commences when 
cognitive deterioration ceases, and behavioural characteristics begin to remerge. This 
stage is complete when the ability to walk is diminished. This final stage, also known as 
the late motor deterioration, is characterised by the loss of gross motor function and is 
generally attributed to atrophy, spasticity and dystonic deformities (Hagberg, 2002; 
Hagberg & Witt Engerstrom, 1986). 
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MECP2 
In 1999 a breakthrough into Rett syndrome research occurred when Amir and colleagues 
identified the association with mutations in the MECP2 gene (Amir et al., 1999) (Figure 
A). The cytogenic location of MECP2 is on the long arm of the X chr01nosome at Xq28 
and is subject to X chromosome inactivation. Mutations of the MECP2 have been 
estimated to be the cause of 70-80% of clinically defined Rett syndrome (Amir, et al., 
1999; Shahbazian, Antallfy, Armstrong, & Zoghbi, 2002). To date more than 200 
MECP2 mutations have been identified with the eight 1nost common representing just 
over two-thirds of mutations positive (Colvin et al., 2004; Bebbington, 2008). These 
eight comtnon mutations occur in the form of missense and nonsense mutations, missense 
mutations are: p.R106W, p.R133C, p.T158M and p.R306C and nonsense mutations are 
the p.R168X, p.R255X, p.R270X and the p.R294X (Neul, 2008). It has also been 
identified that C-terminal mutations, early truncations and large deletion account for an 
additional fifth of mutation positive cases (Young et al., 2008). 
Figure A (MECP2 Gene (Colvin et al., 2003)). 
• R16BX 
l rN~n J 
R2155X 
R270X 
R306C 
8 
• R294X 
RliJSH 
§ 
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Puberty 
There is a paucity of research examining pubertal onset and trajectory in females with 
Rett syndrome. In 1986 Holm in a cross sectional study of 21 girls with Rett syndrome 
was the first to examine sexual development. The average age of menarche was found to 
be 11.2 years. Although research is limited some females with Rett syndrome may 
experience an earlier than expected pubarche (H. Leonard, Thomson, Glasson, Fyfe, 
Leonard, Ellaway, et al., 1999). This is suppmied through families' comments and 
observations on Rettnet, an internet site which provides families with a child with Rett 
syndrome the opportunity to seek and share advice and provide support (H. Leonard et 
al., 2004). 
Growth retardation 
In recent years considerable research in Rett syndrome has focused on growth 
retardation. It is well documented that females with Rett syndrome have decelerated head 
growth and below average body mass index scores; with females with classical Rett 
syndrome displaying lower BMI scores than those with atypical Rett syndrome (Reilly & 
Cass, 2001). The lower BMI scores in Rett syndrome are thought to be the result of 
factors such as feeding difficulties, decreased texture tolerances and disorders of the 
digestive tract, bowel, oromotor and oesophagus (Oddy et al., 2007; Reilly & Cass, 2001; 
Thommessen, Kase, & Heiberg, 1992). 
Bone Dvsmorphologies 
Some research in Rett syndrome has focused on bone dysmorphologies. A cross sectional 
study of 86 girls and women with Rett syndrome reported that 91.3% of cases presented 
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with one or more orthopaedic conditions, the most common of these being scoliosis 
(Hennessay & Haas, 1988; H. Leonard, Fyfe, & Msall, 2001). Several studies have 
examined metacarpal and metatarsal bone length in Rett syndrome cases (Cepollaro et al., 
2001; H. Leonard, Thomson, Glasson, Fyfe, Leonard, Ellaway, et al., 1999; Schultz, 
Glaze, Motil, Hebert, & Percy, 1998). The first study to use metacarpophalangeal pattern 
profile analysis (MCPP) to identify short metatarsals in Rett syndrome was unde1iaken by 
Optiz and colleagues in 1987. These findings of short metatarsals in Rett syndrome were 
,. 
later confirmed in population based studies by Leonard and colleagues (1995) and 
(1999). Leonard et al (1995) rep01ied that 65% of cases (n=11) had short fomih and fifth 
metacarpal bones, and 57% had short fomih and fifth metatarsals (n=8) (H. Leonard, et 
al., 1995). Other bone dysmorphologies described in this study were negative ulna 
variance in 79% (n=ll) of cases and advanced bone age in 56% (n=5). 
A high prevalence of osteopenia, or reduced bone mass, has also been reported in girls 
and women with Rett syndrome. The greater risk that females with Rett syndrome have 
of fractures and reduced bone density (Downs, Bebbington, Woodhead, et al., 2008; 
Haas, Dixon, Smioris, & Hennessay, 1997) compared to females in the normative 
population has been confirmed in population based research. In particular Leonard and 
colleagues (1999) in a study of 101 females identified significantly lower cortical bone 
thickness in Rett syndrome (H. Leonard, Thomson, Glasson, Fyfe, Leonard, Bower, et 
al., 1999). Clearly, girls and women with Rett syndrome are at greater risk of bone 
related diseases due to compromised bone quality. 
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Endocrinology in Rett syndrome 
The findings of abnormal growth patterns in this population along with the observations 
of early pubarche have lead to the hypothesis that there is an underlying endocrinological 
dysfunction in Rett syndrome. This hypothesis is supported by findings from a case study 
in which reported low levels of prolactin and growth hormone were reported in a girl 
with Rett syndrome (Percy & Armstrong, 1988). Huppke et al (2001) in a study of38 
female~, with classical Rett syndrome aimed to determine whether growth hormone 
deficiency was more prevalent in Rett syndrome. In this sample (n=13) individuals had a 
height lower than the third percentile, bone age was delayed in four individuals and 
advanced in three, levels of prolactin, luteinizing hormone (LH), follicle stimulating 
hormone (FSH) and oestradiol were normal and one and two cases presented with 
abnormal scores in thyroxine (T4) and thyroid stimulating hormone (TSH), respectively. 
In addition dehydroepiandrosterone sulphate (DHEAS) levels were low in young females 
and high in older females suggesting a normal onset of andrenarche. Although this study 
was limited by the small sample size and missing data, results from this study pointed to 
signs of an abnormal pattern of hormone secretion, however there was not sufficient 
evidence to determine if growth hormone played a causative role in the growth 
abnormalities displayed in Rett syndrome (Huppke, et al., 2001). 
Further exploration into growth abnormalities in Rett syndrome have been carried out in 
mouse model studies. Mice deficient in MeCP2 have a range of neurological and 
physiological abnormalities which mimic Rett syndrome. Tropea and colleagues (2009) 
investigated the potential oflnsulin-like Growth Factor (IGF-1) when delivered 
systematically to determine if the synaptic and neuronal immaturities which are 
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characteristic ofRett syndrome could be overcome and in turn ameliorate Rett like 
symptoms in a mouse model. This study reported that treatment ofiGF-1 increased PSD-
95 (postsynaptic scaffold protein responsible for synapse maturation, strength and 
plasticity), stabilized cortical plasticity and pmiially restored spine density and synaptic 
amplitude. These findings strongly suggest that IGF-1 has the potential as a successful 
pharmacological treatment in Rett syndrome (Tropea, et al., 2009). 
Genotype, phenotype 
Identification of the lv!ECP2 mutation as a cause ofRett syndrome has enabled 
examination of the relationship between genotype and phenotype expression. However, 
intemationally research in this field has been limited in some countries by a lack of 
population based research and the absence of universal severity scales which would 
enable comparison between samples. The notable exception is the Australian population-
based study which has been recruiting participants through the Australian Rett Syndrome 
Database. Using cases from this database a 2004 study repmied that truncating mutations 
presented with earlier onset of stereotypical hand movements, greater severity using the 
Pineda scale (Monros et al., 2001) and lower functional independence scores suggesting 
that they were causative of a more severe phenotype. Leonards (2003) study comprising 
of (n=ll) Australians, (n=4) Japanese and (n=9) females from the United Kingdom all 
with R133C mutations used four clinical scales; Pineda, Kerr, Percy and WeeFIM to 
compare the phenotype in p.R133C to other mutations. This study identified increased 
hand use and improved ambulation in individual's with p.R133C mutations, a finding 
which was later supported by Colvin et al (2003), Bebbington (2008) and (Neul, 2008). 
Bebbington demonstrated that this mutation along with p.R294X resulted in milder 
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phenotypes, and that p.R270X and p.255X were the most severe phenotypes. It is likely 
that specific genetic mutations influence aspects of puberty in females with Rett 
syndrome differently. It can be hypothesized that mutation type will impact on the onset 
of puberty. 
Down syndrome 
Down syndrome is a chromosomal bilih disorder affecting 1: 1 000 live births making it 
the most prevalent single cause of intellectual disability in Australia (Bower, et al., 2009; 
Petterson, et al., 2005). Although the exact prevalence is unknown it has been identified 
that the overall number ofDown syndrome conceptions has increased since 1980 from 
1.2 /1000 live births to 2.611000 Iivebirths in 2009 (Bower, et al., 2009). This increase 
can be largely attributed to advances in medical care and increased prenatal screening 
(Bittles, Bower, Hussain, & Glasson, 2006; Bower, et al., 2009; Sherman, Allen, Bean, & 
Freeman, 2007). In the past 50 years improvements in medical care have resulted in 
increased life expectancy of individuals with Down syndrome, increasing from 18 to 60 
years of age (Bittles, et al., 2006; Bittles & Glasson, 2004; Weijerman et al., 2008). 
Comorbidities in Down syndrome 
Down syndrome is associated with numerous birth defects with a variety of comorbidities 
(S. Leonard, Bower, Petterson, & Leonard, 2000; K. Thomas, Girdler, Leonard, & 
Downs, 2010). These affect cardiac, respiratory, gastrointestinal, musculoskeletal and 
endocrine systems. Population based, Western Australian research identified that 
approximately 20% of children with Down syndrome experienced four or more medical 
conditions. The most common comorbidity seen in Down syndrome was cardiac disease 
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with estimates of 46% of Western Australian children with Down syndrome presenting 
with some form of cardiac disorder (S. Leonard, et al., 2000). 
Puberty in Down syndrome 
Although still limited, a greater body of research has examined the trajectory of puberty 
in females with Down syndrome than those with Rett syndrome. However, the majority 
of this research has focused on age of menarche with very few examining the overall 
pubertal trajectory. Arnell, Gustafasson, Ivarson and Anneren (1996) in a longitudinal 
study of males (n=23) and females (n=21) with Down syndrome over the age often 
years, repmied that a pubertal growth spmi occurred early but remained lower than in the 
normative population. The mean age of menarche was 13.2 years (11.8-16.2). Similarly a 
cross sectional study by Scola, Seigfried and Pueschel (1992) with a sample of girls 
(n=51) with Down syndrome repmied the average age of menarche to be 12.6 years (10-
16). Both these studies indicate that pubertal onset occurs at an age similar to that of the 
normative population (F. Thomas, et al., 2001). 
Thyroid Function in Down syndrome 
The most prevalent endocrine abnormalities in Down are diabetes and thyroid disease 
(Gibson et al., 2005; Hawli, Nasrallah, & Fuleihan, 2009). A large propmiion of studies 
exploring thyroid function in Down syndrome have been cross sectional on non-
population based samples. In 2006 Gibson commenced a longitudinal study aimed at 
measuring the prevalence and type of thyroid dysfunction (TD) in children in the United 
Kingdom (n=122) with Down syndrome ranging in age from 6 to 14 years. A follow up 
study was able to contact 104 children and young people between four and six years later. 
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The first assessment revealed 98 euthyroid individuals and of these 83 were retested and 
four (5%) were found to have hyperthyrotropinaemia (isolated raised thyroid stimulating 
hormone). Of the 24 children found to have hyperthyrotropinaemia in 2006 14/24 had 
returned to normal at follow-up. 10/24 (41%) still presented with thyroid abnormalities. 
A longitudinal study by Prasher and Gomez of 200 individuals with Down syndrome 
testing for thyroid dysfunction at one year, five year and ten year reported that at baseline 
testing) 1% of cases had subclinical hypothyroidism, 10.5% had definite hypothyroidism 
and 3% were biochemically hypothyroid. At five years follow up (n=104) 19% of 
individuals were on thyroxin and 28% of individuals had abnormal thyroid function tests. 
By the final assessment at ten years follow-up, the study group had dropped to 49 and of 
these 35% were on thyroxin and 37% had abnormal thyroid function tests. These findings 
confirm the high prevalence and incidence of thyroid dysfunction within Down 
syndrome, particularly hypothyroidism (Prasher & Gomez, 2007). Hypothyroidism can 
affect an individual's life in numerous ways such as weight gain and delayed puberty. 
Delayed puberty is the absence of secondary sex characteristics by the age of thirteen, no 
signs of menarche by the age of sixteen, and a period of five or more years between the 
development of secondary sex characteristics and menarche (Shah, 1997). 
Weight in Down syndrome 
A considerable body of research has described a relationship between Down syndrome 
and a high body mass index and a lower than normal resting metabolic rate (Melville, 
Cooper, McGrother, Thorp, & Collacott, 2005). Research in the nonnative population has 
supported that there is a positive association between increased BMI scores and earlier 
onset of puberty, (Buyken, Karaolis-Danckert, & Remer, 2009; Lin-Su, Vogiatzi, & New, 
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2002). However, although an association has been established, the causative nature of 
this relationship remains unclear. It is not known whether increased body fat is the cause 
or the result of decreased age of pubertal onset. Clearly there is a need for further 
research to be conducted with larger sample sizes and more robust methodologies. 
Menstruation 
For women with Rett syndrome or Down syndrome multiple factors determine, whether 
monthly menstruation results in a mild inconvenience or a major health concern (Kaur, 
Butler, & Trumble, 2003). As no literature has specifically examined issues in relation to 
these two disorders, literature pertaining to all intellectual disability has been examined in 
this review. In females with an intellectual disability menstrual management frequently 
results in many issues and concerns (Kaur, et al., 2003), which can be broadly categorised 
into self care, menstrual disorders and sexual health (McEvoy, Chang, & Coupey, 2004). 
Self Care o(menstruation 
The onset of menstruation can be a confusing transition for all females, particularly if the 
individual has not been made aware or educated in these issues (McEvoy, et al., 2004). 
Research on females with an intellectual disability have identified that many do not 
receive adequate preparation for the onset of puberty (Lin & Barnhart, 2007; McEvoy, et 
al., 2004). A randomised control study (n=7770) in England explored methods of sexual 
education finding that in the normative population peer based programmes were valued 
greater than programmes run by teachers. The main reasons for this were better timing of 
programmes and a wider variety of content (Forrest, Strange, & Oakley, 2002). It has 
been reported that females with an intellectual disability often have fewer friendships and 
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peer relationships suggesting they are less likely to receive sexual education through this 
avenue (Strully & Strully, 1985). The combination of impaired cognitive ability and lack 
of education may result in females with Rett syndrome and Down syndrome feeling very 
confused and distressed during the commencement of menstruation (Quint, 2008). 
Factors such as impaired physical mobility and upper limb functioning may also impact 
on the young women with intellectual disabilities ability to manage self-care during 
menstruc;ttion (Quint, 2008). In females with Down syndrome severity of intellectual and 
physical impairment varies widely. Physical impairment is likely to be a greater factor in 
Rett syndrome as both upper and lower limb impairment have been reported in this 
population. A video analysis study in 2008 explored the gross motor profile in Rett 
syndrome cases (n=99). Findings were that the majority of girls with Rett syndrome were 
able to sit independently, approximately 50% were able to walk and a minority were able 
to independently transfer (Downs, Bebbington, Msall, et al., 2008). The varying severity 
in both Rett syndrome and Down syndrome indicates that managing the hygiene aspects 
of menstrual management may be possible for some but not for many individuals within 
these populations. 
Menstrual Disorders 
There is a wide variety of disorders associated with menstruation. Common disorders 
include dysmenorrhoea menorrhagia, polycystic ovary syndrome, pre-menstrual 
syndrome and catamenial epilepsy (Lin & Barnhart, 2007; Weatherford, 1999). No 
research into issues relating to menstrual disorders in Rett syndrome has been identified. 
However research into Down syndrome (n=59) has reported menorrhagia in 30% of 
females (Mason & Cunningham, 2008). Epilepsy is a highly prevalent disorder in 
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individuals with an intellectual disability with an estimated population prevalence of 20 
%. In samples of girls and women with Rett syndrome (n=53) prevalence estimates have 
been repmied to be as high as 94% (Steffenburg, Hagberg, & Hagberg, 2001). Similarly 
high rates (81%) were identified in a population based study by Jian and colleagues of 
females with Rett syndrome (n=275) where the average age of onset was four years of 
age (Interquartile range IQR 24-90 months) (Jian et al., 2006). A further study by Jian 
and colleagues repmied that among this population higher rates of seizure frequency were 
,. 
more likely in females with lower functional ability and higher clinical severity (Jian et 
al., 2007). Genotype was identified as a contributing factor with p.R294X, p.R255X and 
C terminal mutations having lower frequencies of seizures (Jian, et al., 2007). Seizure 
frequency has also been found to be influenced by age, Jian and colleagues reporting the 
highest frequency of seizures in the 7-12 year age group. In an earlier non-population-
based study, Leonard and colleagues (200 1) reported that the prevalence of seizure 
diagnosis increased from 22.1% in those less than five years of age to 88.9% for 
individuals over the age of 14 years. Studies exploring epilepsy in Down syndrome have 
reported lower prevalence (17%) than Rett syndrome but still higher than in the 
normative population (Johannsen, Christensen, Goldstein, Nielsen, & Mai, 1996; 
Me Vicker, Shanks, & McClelland, 1994). This high prevalence of epilepsy within Rett 
syndrome and Down syndrome indicate that catamenial epilepsy could be a potential 
problem in the management of menstruation. 
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Sexual Health 
Sexuality is an area of concern for individuals with an intellectual disability and their 
families (Isler, Tas, Beytut, & ConK, 2009). Research has repmied that individuals with 
an intellectual disability are at a greater risk of contracting sexually transmitted diseases 
(STDs), having unplanned pregnancies and are three times more likely to be the victim of 
sexual abuse than the normative population (Nosek, et al., 2001; WHO & UNFPA). 
These otitcomes are thought to be the result of their high dependency levels and the lack 
of education provided to both the individuals with an intellectual disability, their families 
and the wider community (Nosek, et al., 2001). Contraception is often used by 
individuals with an intellectual disability to prevent unplanned pregnancies however 
contraception does not prevent STDs or abuse. These findings highlight the impmiance 
of educating individuals with an intellectual disability and their families about the risks 
and about methods of reducing these risks. 
Managing Menstruation 
The methods employed in managing menstruation can be described in three categories: 
medical suppression; elimination; and, self management (Albanese & Hopper, 2007; 
Paransky & Zurawin, 2003; Pillai, O'Brian, & Hill, 2009; Quint, 1991). Research 
examining the management of menstruation in females with an intellectual disability is 
limited however overall seems to support the conclusion that menstrual suppression is the 
most common approach (Pillai, et al., 2009). There are a number of methods of menstrual 
suppression available to females with an intellectual disability. However their 
prescription is influenced by the complex medical complications seen in this population 
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(Kaur, et al., 2003). Both medical and surgical methods of suppression are available. 
Medical interventions include oral contraceptives (OCP), oral progesterone's, depot 
medroxy progesterone acetate (DMPA) and gonadotrophin releasing hormones (GnRH) 
(Albanese & Hopper, 2007). 
Suppression o[menstruation 
Research into the use of suppression as a method of menstrual management in Rett 
syndrome and Down syndrome is very limited. A population based study (n=397) in 
Brussels explored the use of suppression in females with all levels of intellectual 
disability aged between 18 and 46 years (mean ±SD= 33.62 ±7.17yrs). It was found that 
18% used OCP (n=73), 17.6% used DMPA (n=70), and 40.8% used no form of 
suppressant (n=162). Comparison with the general population in Brussels highlighted that 
women with intellectual disability were more likely to use DMPA (17.6% compared to 
2%) (Servais et al., 2002). These findings highlight the difference between menstrual 
management and contraceptive methods used in females with an intellectual disability to 
those used in the general population. 
Depot medroxv progesterone acetate (DMPA, Depot Provera, Depot-Ralovera) 
DMP A is a frequently used suppressant in females with an intellectual disability and is 
effective as both a suppressant and a contraceptive (Albanese & Hopper, 2007; Dizon, 
Allen, & Ornstein, 2005; Watson, Lentz, & Cain, 2006). DMPA is a progesterone only 
drug and is administered quarterly through an intra muscular injection. This drug 
suppresses menstruation through suppressing pituitary gonadotrophin resulting in 
anovulation, endometrial atrophy and hypoestrogenemia. DMPA has been associated 
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with negative health outcomes such as hair loss, cancer and weight gain (Paul, Skegg, & 
Spears, 1989; Stager & Cromer, 2000; Watson, et al., 2006). Weight gain may be a 
pmiicular concern for females with Down syndrome as high rates of obesity have been 
documented within this population (Melville, et al., 2005). However probably the most 
important factor to consider in the prescription ofDMPA to women with Down 
syndrome and Rett syndrome is its reported association with decreased bone density 
(Guilbert et al., 2009; Kass-Wolff, 2001; Pongsatha, Elkmahachai, Chaovisitsaree, 
,-
Suntornlimsiri, & Morakote, 2009; Watson, et al., 2006). Additionally, for some 
individuals an intramuscular injection may be too traumatising. In these cases oral 
progesterone is available however the effectiveness of this is reduced due to the high 
incidence ofbreakthrough bleeding (Albanese & Hopper, 2007). 
Oral Contraceptive Pill 
The continuous use of oral contraceptive pills is another frequently used method in 
females with an intellectual disability (Schrager, 2009). This is a combination of 
oestrogen and progesterone and is usually taken in the form of nine weeks of continuous 
use followed by a break on the 1oth week. Reported side effects of OCP use are increased 
risks of venous thrombosis (Vandenbroucke et al., 2001), slightly increased risks of 
breast cancer and decreased bone density (Hannaford, Kay, Vessey, Painter, & Mant, 
1997). A study conducted by Stadel (1981) identified that the risk of venous thrombosis 
was fourfold in females using the oral contraceptive pill, this study is relatively old and 
changes to the dosages of oral contraceptives have been made since. A more recent study 
conducted by the World Health Organization in 1998 identified equally high risks (3-6 
times) of thrombosis in OCP users. This study also identified that the risk was greatest 
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during the first year of use and increased up to but not beyond discontinuation (WHO, 
1998). Thrombosis is a particular concern for girls and women with Rett syndrome as 
many females with Rett syndrome have decreased mobility (Weiner, 1999). As in DMPA 
the use of OCP has been repmied to decrease bone density, however this is to a lesser 
extent than the risks ofDMPA and is dependent on the dosage taken (Balasch, 2003). It is 
unclear as to whether the use of OCP increase the risk of Breast Cancer, one study 
conducted in USA in 2002 explored this relationship in a sample of (n=4575) females 
between 35 and 64 years of age, and a control group of (n=4682). This study identified 
that current use or former use of the OCP was not significantly associated with increased 
risks of breast cancer (Marchbanks et al., 2002). 
MIRENA 
In addition to medical suppressants surgical options are available, the most common of 
which is the levongestrel intrauterine system (MIRENA) or LNG-IUS. The LNG-IUS is a 
32mm plastic device containing progesterone levongestrel that suppresses menstruation 
through releasing the progesterone levongestrel over a five year period (Pillai, et al., 
2009). It results in local oestrogen insensitivity which inhibits endometrial proliferation. 
For females with Rett syndrome the LNG-IUS may need to be inserted under a general 
anaesthetic which may be traumatising for an individual and consent is needed. 
Commonly arising issues associated with LNG-IUS are breakthrough bleeding, cysts, 
bloating and weight gain (Albanese & Hopper, 2007; Freeman & Shulman, 2010). 
Research examining menstrual suppression in both females with an intellectual disability 
and the normative population highlights the numerous side effects associated with each 
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suppressant. This suggests that there is no 'perfect option' and that numerous factors such 
as medical history and medical comorbidities need to be taken into consideration before 
any suppressant is prescribed. The association between many of the methods and 
decreased BMD is an important consideration as adolescents is a period in which bone 
mass production reaches its peak and females with Rett syndrome (Budden & Gunness, 
2003; H. Leonard, Thomson, Glasson, Fyfe, Leonard, Bower, et al., 1999) and Down 
syndrome (Angelopolulou, Souftas, Sakadamis, & Mandroukas, 1999; Balasch, 2003; 
' 
Bapista, Varela, & Sardinha, 2005) have already decreased bone densities. 
Elimination o[menstruation 
Elimination of menstruation is available through two surgical operations, endometrial 
ablation and hysterectomy. Hysterectomy is the removal of all or part of the ovaries, 
fallopian tubes, uterus and cervix whereas endometrial ablation is the removal of all of 
the endometrium and part of the myometrium. (Paddison, 2003; Torpy, Lynm, & Glass, 
2004). In many countries the sterilization of females with an intellectual disability is an 
area of great controversy. This is largely due to their inability to provide consent and 
concern in relation to contravention of human rights. It is well documented that females 
with an intellectual disability are more likely to be sterilized and at an earlier age than 
females in the normative population (Servais, et al., 2002; Stansfield, Holland, & Clare, 
2007). Stanfield and colleagues (2007) conducted a retrospective case note study of 
referrals made to the "Official Solicitor's Office for Sterilization" in England and Wales 
between 1988-1999. Over the 11 years approval for sterilization was sought through the 
court for 39 females. In three quarters (n=31) of cases sterilization was deemed to be in 
the persons best interest. This study also explored the reasons for sterilization. The most 
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common reason was elimination of the risk of pregnancy (n= 22) and other reasons stated 
were difficulties managing menstruation (n=3), side effects of suppressants (n=5) and the 
carer's difficulty in managing the individuals menstruation (n=4). 
Sterilization of females with an intellectual disability can be considered either therapeutic 
or non-therapeutic sterilization. Therapeutic sterilization refers to sterilization carried out 
to prevent ill health or death whereas non therapeutic sterilization is predominately to 
prevent pregnancy or reduce issues in the management of menstruation (Brady, 2001) 
Australian legislation is strongly against non therapeutic sterilization however this may 
still be carried out in some females if sterilization is deemed to be in the individuals "best 
interest" (AHRC, 1997). Servais study conducted in Brussels (n=397) identified that 
22.2% of females with an intellectual disability were sterilised (n=88) this is a very high 
rate when compared to the normative population in Brussels which identified that 7% of 
females had undergone eliminating surgery (Servais, et al., 2002). This research into 
sterilization of females with intellectual disability highlights the issues and controversies 
associated with sterilization in this population. As sterilization is a permanent procedure 
it should only be carried out as a last resoti once all other options have been exhausted 
(Brady, 2001). 
Sel[Management o[menstruation 
The literature into the various side effects associated with suppressants suggests that self 
management is a suitable method in managing menstruation for some individuals, It has 
been identified that approximately 33% of females with an intellectual disability are able 
to independently manage menstruation (Rodgers & Lipscombe, 2005). Mason and 
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Cunningham (2008) in a study of (n=6) young women with Down syndrome and (n=53) 
mothers of girls with Down syndrome reported that 60% of cases were independent in 
managing menstruation with no or very limited assistance. There is currently no research 
exploring self management of menstruation in females with Rett syndrome however the 
severity of intellectual disability, high levels of dependence and reduced hand functioning 
of these women suggests that for the vast majority self management may be difficult. 
Females with Rett syndrome have a high prevalence of incontinence implying that 
' 
management of hygiene in menstruation may be managed similarly to everyday 
continence hygiene (H. Leonard, et al., 2001). In order for self management to be 
successful individuals and their families need to be educated on the topic before puberty 
commences to reduce the distress the individual experiences. 
Discussion 
This narrative review found that there are some factors suppmiing the hypothesis that 
pubertal trajectory may be abnormal in females with Rett syndrome and Down syndrome 
and that there are likely to be many issues which need to be taken into consideration 
when selecting an appropriate method of menstrual management in this population. 
Limitations of this review were the paucity of research into this field which resulted in 
studies that were cross sectional and longitudinal being used, and studies were not always 
population based. These factors along with the importance of the subject highlights the 
need for more studies with population based samples to be carried out. 
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Conclusion 
Although there is a paucity of research examining puberty in Rett syndrome, the 
identification of decreased bone mineral densities and growth retardation along with the 
observations of early signs ofpubarche strongly suggest an underlying endocrine 
dysfunction is present in Rett syndrome. These findings imply that the onset of pubetiy 
and pubertal trajectory may be different from normal. It is also possible that the wide 
phenotypic spectrum may influence aspects of puberty as varying levels of severity have 
been linked to different mutations (Colvin, et al., 2003; Bebbington, 2008). 
Research into Down syndrome highlighted the high prevalence of thyroid dysfunction, 
many ofthese studies focused on the high incidence of hypothyroidism, suggesting that 
puberty may be delayed in many females with Down syndrome. The majority of these 
studies have lacked generalisability due to small sample sizes and weak methodologies 
(Gibson, et al., 2005; Prasher, 2007). 
Research into menstrual issues and management was limited in both the fields ofRett 
syndrome and Down syndrome resulting in this review including literature pertaining to 
intellectual disability in general. This research highlighted common issues to be hygiene, 
sexual health and menstrual disorders particularly catamenial epilepsy. The high 
prevalence of epilepsy in females with Rett syndrome and to a lesser extent in Down 
syndrome may have a significant impact on the methods of menstrual management due to 
increased seizures during menstruation (Jian, et al., 2007; Johannsen, 1996). This is likely 
to result in the use of menstrual suppressants as a preferred management technique. 
Another area of concern in both Rett syndrome and Down syndrome is the increased risk 
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of sexually transmitted diseases, abuse and unplanned pregnancies. The increased risk of 
unplanned pregnancies was reported to be a leading factor in the increased rates of 
sterilization and menstrual suppression in females with an intellectual disability (AHRC, 
1997) 
Overall the reviewed research highlighted that there are both advantages and 
disadvantages associated with the use of menstrual suppressants for females with Rett 
syndrome and Down syndrome. Many ofthe medical suppressants were found to have 
serious health consequences such as decreased bone density, venous thrombosis, and 
slightly increased risks of breast cancer. For individuals with Rett syndrome or Down 
syndrome the greatest concerns are that of decreased bone density which was found to be 
caused by OCP but more so by DMPA, this is a concern for females with Rett syndrome 
and Down syndrome as these individuals have been found to have already decreased 
bone density. Venous thrombosis is another area of concern particularly in Rett syndrome 
as many females with Rett syndrome have reduced mobility (Downs, Bebbington, Msall, 
et al., 2008; Weiner, 1999), increased risks of venous thrombosis were found to be 
associated with the use of OCP (Stadel, 1981; WHO, 1998). Advantages of menstrual 
suppressants are the elimination of issues relating to managing hygiene and the reduction 
of seizure activity. The studies into this area highlight that use of suppressants is very 
individualised and in females with Rett syndrome and Down syndrome aspects such as 
comorbidities, family medical history and mobility need to be considered before any 
method is selected. This review also identified high rates of sterilization in females with 
an intellectual disability in comparison to the normative population, making it an ongoing 
topic of controversy due to the contravention of human rights. Sterilization may be a 
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suitable option for some individuals however should only be considered if it is 
therapeutic (Stansfield, et al., 2007). 
Cunently very few studies explore pubertal trajectory or menstrual management in 
females with Rett syndrome and Down syndrome and those that do often use small 
sample sizes and lack methodological quality. The review identified numerous factors 
which may impact on the pubertal trajectory within these populations and identified a 
wide range of factors which may influence the methods of menstrual management used in 
these females. 
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N; Bower, C; cumulative incidence and survival in syndrome of age 
Christodoulou, J; Ravine, an Australian cohort with Rett (RS) 
D; et al syndrome 
Hagberg, B; Witt 1986 To develop a staging system to Longitudinal 29RS N/A 4 stage system for 
Engerstrom facilitate the categorisation of Mean=18 classical RS 
disease patterns and profiles from Range=13-. developed 
infancy to adolescence in RS 28 
Amir, R; VanDer 1999 Determine a cause of Rett syndrome Cross sectional 21RS N/A Systematic gene 
Veyver, I; Wan, M;Tran, through genetic screening screening identified 
C; Francke, U; et al MECP2 as cause 
Holm, V 1986 Determine linear growth and sexual Cross sectional 21 RS ARSD Average menarche 
development in females with RS Mean=9.8 =11.2 
Leonard, H; Slack-Smith, 2004 To determine the value of an email Cross sectional 119RS Rettnet 81.5% valued Rettnet 
L;Phillips, T; Richardson, listserve for parents of children with as a support network 
S; D'Orsonga, et al RS 
Authors Year Objective Methodology Participant Database Main Findings 
~. 
Leonard, H; Thomson, 1999 To compare bone mass using hand Cross sectional 137RS ARSD 33.3%had fracture 
M; Glasson, E; Fyfe, S; radiographs between females with Population Bone quality 
Leonard, S; et al RS and a control group based compromised 
Leonard, H; Thomson, 1995 To identify the presence ofbone Cross sectional 19 RS ARSD Short metacarpal and 
M; Bower, C; Fyfe, S; dysmorphologies in females with RS Range=S-37 metatarsal bones 
Constantinou, J 
Leonard, H; Colvin, L; 2003 Identify the phenotype of p.Rl33C Cross sectional 11 from ARSD Rl33C milder 
Christodoulou, J; in three countries International Australia phenotype 
Schiavello, S; com pans on 4 Japan 
9UKRS 
Leonard, H; Thomson, 1999 Determine bone age in females with Cross sectional 100 RS ARSD Bone age advanced in 
M; Glasson, E; Fyfe, S; RS Population >20yrs of Rett syndrome 
Leonard, S; et al based age 
Downs, J; Bebbington, 2008 Use video analysis to identify gross Cross sectional 99RS ARSD p.Rl33C, p.R294X 
A; Msall, M; Mcilroy, 0; motor profile in RS Population and p.R225X milder 
Fyfe, et al based 
Authors Year Objective Methodology Participant Database Main Findings 
~-
Huppke, P; Roth, C; 2001 Identify if GH plays a causative role Cross sectional 38RS paediatric Not sufficient 
Christen, H; Brockman, in the growth retardation seen in RS Department evidence for GH as 
K; Hanefeld, F Gottingen cause of growth 
retardation 
Colvin, L; Fyfe, S; 2003 Describe the variation in phenotype Longitudinal 199 RS ARSD Used Percy, Pineda, 
Leonard, H; Schiavello, in RS using pineda, Percy, Kerr and Population Kerr and W eeFIM 
S; Ellaway, et al WeeFIM based scales 
Bebbington, A; 2008 Examine the genotype phenotype Cross sectional 272RS IntreRett p.R270X and 
Anderson, A; Ravine, D; relationships in RS Population p.R225X more sever 
Fyfe, S; Pineda, M; et al based phenotype 
Bittles, A; Bower, C; 2006 Identify four ages ofDS, prenatal, Longitudinal 1332 Down Birth Defects 4 life stages identified 
Hussain, R; Glasson, E childhood and early adulthood, Population syndrome Registry 
adulthood and senescence based (DS) 
Arnell, H; Gustaffasson, 1996 Identify the growth and pubertal Cross sectional 44DS Health Average age of 
J; Ivarsson, S; Anneren, development in females with DS Range 10- Records menarche 13 .2 
G 24 Uppsala 
Authors Year Objective Methodology Participant Database Main Findings 
Scola, P; Siegfried, M; 1992 Detennine average age of menarche Cross sectional 51 DS N/A Average age of 
Pueschel, M in a sample of females with DS Range 10- menarche 12.6 
27 
Gibson, P; Newton, R; 2006 Identify the pattern of thyroid Longitudinal 122DS Hester Adam Increased prevalence 
Selby, K, Price, D; dysfunction present in DS Population Research thyroid dysfunction 
Leyland, et al based Centre 
-
Prasher, V; Gomez, G 2007 Investigate mmual thyroid function Longitudinal 200 UK Increased prevalence 
tests in females with DS to identifY Population thyroid dysfunction 
abnormalities based 
Melville, C; Cooper, S; 2005 IdentifY the prevalence of obesity in Cross sectional 247 Leicestershire Increased prevalence 
McGrother, C; Thorp, C; individuals with DS Case control Learning Obesity 
Collacott, R study Disability 
Register 
Leonard, S; Bower, C; 2000 Evaluate changes in survival from Longitudinal 440 WA birth Improvements in 
Petterson, B; Leonard, H birth in individuals with DS Population defects survival rates 
registry 
Forrest, S; Strange, V; 2002 Compare students views on teacher Cross sectional 7770 RCT English Peer programmes 
Oakley, A and peer led education programmes Schools higher valued 
Authors Year Objective Methodology Participant Database Main Findings 
Mason, L; Cunningham, 2008 Explore the issues experienced in Cross sectional 59 N/A 60~independentin 
c menstruation in females with DS 53=mothers managing 
menstruation 
Steffen burg, U; Hagberg, 2001 Identify the prevalence of epilepsy Cross sectional 53 All known Increased prevalence 
G; Hagberg, B in females with RS RS cases in of Epilepsy 
Sweden 
Jian, L; Nagarajan, L; De 2007 Investigate seizure frequency and its Longitudinal 162 ARSD Highest in 7-12 year 
Klerk, N; Ravine, D; relationship with other factors such age group 
Christodoulou, J; et al as genetics and medication in 
females with RS 
Jian, L; Nagarajan, L; De 2006 Identify risk factors for seizure onset Longitudinal 275 ARSD Average age of onset 
Klerk, N; Ravine, D; in Rett syndrome Population =48 months 
Bower, C; et al based 
Joham1sen, P; 1996 Identify the prevalence of epilepsy Cross sectional 71 Danish Increased prevalence 
Christensen, J; Goldstein, in DS in three age groups (14-16 register or 
H; Neilsen, V; Mai, J years, 23-29 years and 50-60 years) mental 
retardation 
Authors Year Objective Methodology Participant Database Main Findings 
~, 
Albanese, A; Hopper, N 2007 Provide an account of the various Review N/A N/A Wide variety of side 
therapeutic suppressant options effects associated 
available to females with ID with suppressants 
Pillai, M; O'Brian, K; 2009 Investigate the experience of females Longitudinal 14 GP referral Found to be 
Hill, E with a disability using LNG-IUS Range=11- therapeutically 
21 beneficial 
Servais, L; Jaques, D; 2002 Identify the methods of Cross sectional 397 Government 
Leach, R; Conod, L; contraception used in females with Population Range 18- facilities in 
Hoyois, P; et al ID compared to the normative based 46 Brussels 
population 
Dizon, C; Allen, L; 2005 Define the clinical characteristics of, Retrospective 72 Toronto DMP A most common 
Ornstein, M and management options offered to chart review Range 8-17 Hospital 
young women with developmental 
delay 
Watson, K; Lentz, M; 2006 Evaluate any association between Cross sectional 6773 DMP A resulted in 
Cain, K osteoporotic fractures and the use of Population 2::13 years of increased risk of 
DMPA based age fractures 
Authors Year Objective Methodology Participant Database Main Findings 
~, 
Angelopolulou, N; 1999 Elucidate if individuals with DS are Cross sectional 22 (9 males N/A Decreased Bone 
Souftas, V; Sakadamis, likely to experience an increased risk 13 females mineral density 
A; Mandroukas, K of osteoporosis with advancing age 
Bapista, F; Varela, A; 2005 Compare bone mineral mass in Cross sectional 134 Training Decreased Bone 
Sardinha, L females and males with DS Range=l4- centres mineral density 
40 Lisbon 
Guijarro, M; Valero, C; 2008 Determine the anthropometric and Cross sectional 39 Marques de Decreased bone 
Paule, B; Gonzalez- lifestyle factors influencing bone Mean=26 Valdealla mineral density 
Macais, J; Riancho, J mineral density in DS 78 controls Hospital 
Stansfield, A; Holland, 2007 Identify the number of and reason Retrospective 73 Official Increased rates of 
A; Clare, I for sterilization of females with ID case note study solicitors sterilization 
office 
Notes 
a RS stands for Rett syndrome 
b DS stands for Down syndrome 
c ARSD stands for Australian Rett syndrome Database 
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Pubertal Trajectory and the Management of Menstruation in Females with Rett 
syndrome and Down syndrome 
Background: Growth retardation, low bone mass, osteopenia and bone dysmorphologies 
have all been identified as clinical features of Rett syndrome, suggesting the presence of an 
underlying neuroendocrine disorder. Research into Down syndrome has repmied high 
incidences of comorbidities patiicularly thyroid dysfunction. Theses findings into Rett 
syndrome and Down syndrome suggests that pubertal trajectory and other aspects of puberty 
may be abnormal for these populations. The aim of this study was to determine the pubertal 
trajectory and methods of menstrual management in females with Rett syndrome and Down 
syndrome. 
Methods This research used data from two sets of surveys. The Rett syndrome component of 
the study Wfl.S based on six waves of longitudinal data (1996, 2000, 2002, 2004, 2006 and 
2009) collected through the Australian Rett Syndrome Surveys. The Down syndrome data for 
the curr-ent study was based on information collected in the Down Syndrome Needs Opinions 
and Wishes (NOW) questionnaire 2004. Survival analysis was used in determining the 
pubetial trajectory using the Kaplan Meier method and life tables to calculate survivor 
estimates. The relationship of genotype and Body mass index on pubetial trajectory was 
analysed using Cox Proportional Hazards Method. The menstrual management component of 
the study was analysed using descriptive statistics and regression. 
Results In Rett syndrome the median age to reach Tanners stage two was 11 years, and the 
median age of menarche was 14years. The duration between the two milestones was greatest 
in individuals who reached Tanners stage two earliest. Body mass index and genotype were 
found to have an impact, with high BMI resulting in earlier onsets. In Down syndrome the 
median age to the first sign of pubetiy and menarche was 12 years of age. In Rett syndrome 
and Down syndrome the most commonly used suppressant was the oral contraceptive pill. 
The most frequently experienced issues were increased seizure activity in Rett syndrome and 
difficulty understanding in Down. 
Discussion Pubertal trajectory in Rett syndrome was delayed compared to that of the 
normative population, In Down syndrome the trajectory was very similar to that of the 
normative population. The use of menstrual suppressants was much greater in females with 
Rett syndrome and Down syndrome than in the normative population, this is a concern due to 
the serious health concerns associated with the use of suppressants. 
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Pubertal Trajectory and the Management of Menstruation in Females with Rett 
syndrome and Down syndrome 
Puberty is the transitional stage between childhood and adulthood (Terasawa & Fernandez, 
2001 ). In females it is a complex process regulated by adrenarche and gonadarche; two 
independent processes responsible for the development of ovaries, secondary sex 
characteristics, increased honnone levels, menstruation and ultimately fertility (Ellis, 2004; 
Plant & Barker-Gibb, 2004). The sequential series of physical changes that cumulate in 
,. 
sexual maturity were described by Dr James Tanner. Tarmer stage one denotes the 
prepubescent stage where there is no observable sexual development; stages two through five 
are the four stages of puberty which can be displayed through a visual scale (see Figure A 
and B) (Marshall & Tanner, 1969) 
Fintre 2 fTanner hreast develnnment) 
lk -A\ r 1 r 
Fif!ure I fTanner nuhic hair develnmnent 
(r ' \ / \ . / r T 
(Marshall & Tanner, 1969). 
Due to its challenging nature and observations that the average age of onset of puberty is 
getting younger, pubertal onset has been frequently studied across the world within normative 
populations (Denzer et al. , 2007; Kaplowitz, 2008 ; Onland-Moret et al. , 2005). However, 
limited research has examined the pubertal trajectory of individuals with an intellectual 
disability. The cognitive, as well as physical impairments and comorbidities often 
experienced by girls and women with intellectual disability suggest that puberty may pose 
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additional challenges for this population. This study aimed to explore the pubmial trajectory 
and management of menstmation in two syndromes within intellectual disability, Rett 
syndrome and Down syndrome. 
Rett syndrome is a severe neurodevelopmental disorder that almost exclusively affects 
females (Mount, Hastings, Reily, Cass, & Charman, 2001). It is a leading cause of severe 
intellectual disability affecting 1:9000 female bilihs (Laurvick et al., 2006). In 1999, 
breakthrough research by Amir and colleagues identified mutations in the MECP 2 gene as 
the cause ofRett syndrome (Amir et al., 1999). However more than 200 MECP2 mutations 
have now been described with the eight most common being; p.R106W, p.R133C, p.T158M, 
p.R306C, p.R168X, p.R255X, p.R270X and the p.R294X (Neul, 2008). 
To date only one study by Holm (1986) has examined the average age of menarche in (n = 
21) girls with Rett syndrome, reporting the average age on onset to be 11.2 years. However, 
early pubarche has also been reported (H. Leonard, Thomson, Glasson, Fyfe, Leonard, 
Ellaway, et al., 1999). This finding, along with population based studies that have 
documented growth retardation, low bone mass, osteopenia and bone dysmorphologies as 
clinical features ofRett syndrome suggests the possibility of an underlying neuroendocrine 
disorder in Rett syndrome (Huppke, Roth, Christen, Brockmann, & Hanefeld, 2001; H. 
Leonard, Thomson, Bower, Fyfe, & Constantinou, 1995; H. Leonard, Thomson, Glasson, 
Fyfe, Leonard, Bower, et al., 1999; H. Leonard, Thomson, Glasson, Fyfe, Leonard, Ellaway, 
et al., 1999). 
Down syndrome is a chromosomal birth disorder affecting 1 : 1000 live births and is the most 
common cause of intellectual disability in Australia (Bower et al., 2009; S. Leonard, Bower, 
Petterson, & Leonard, 2000; Petterson et al., 2005). Although still limited, there has been 
more research examining the trajectory of puberty in females with Down syndrome than in 
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Rett syndrome. One study of (n = 21) females with Down syndrome identified the mean age 
of menarche to be 13.2 years, range (11.8, 16.2) (Arnell, Gustafasson, Ivarsson, & Anneren, 
1996) a similar study reported the age of menarche in a sample of 51 girls with Down 
syndrome to be 12.6 years, range (1 0, 16) (Scola, Siegfried, & Pueschel, 1992). Although 
more research has been conducted in this population it has involved small sample sizes and 
did not use population based samples. Research into Down syndrome has documented a wide 
range of comorbidities with thyroid dysfunction being among the most common (Gibson et 
al., 2005; Hawli, Nasrallah, & Fuleihan, 2009). Thyroid dysfunction pmiicularly 
hypothyroidism has been repmied to greatly impact pubertal timing suggesting that 
individuals with Down syndrome may experience abnormal pubertal trajectory (Prasher & 
Gomez, 2007). 
Methods Rett syndrome 
This research used data from two sets of surveys, longitudinal Rett syndrome surveys and the 
Down syndrome 2004 survey. The Rett syndrome component of the study was based on six 
waves of quantitative data collected through follow-up questionnaires administered in 1996, 
2000, 2002, 2004, 2006 and 2009 to parents of girls and women with Rett syndrome recruited 
through the Australian Rett Syndrome Database (ARSD) (H Leonard, C Bower, & D English, 
1997). The ARSD is a population based database of clinically or genetically diagnosed Rett 
syndrome cases living in Australia and born since 1976. The database was established in 
1993 and cases have been sourced through the Australian Paediatric Surveillance Unit, the 
parent group, the Rett Syndrome Association of Australia and referring doctors (H. Leonard, 
C. Bower, & D. English, 1997). The current study included confirmed female cases whose 
parents or carers and had answered the pubetiy section of at least one of the six waves of 
questionnaires. 
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Data Management and Analysis 
All data was de-identified and stored electronically on Filemaker Pro databases (FileMaker, 
2010). Further to cleaning and coding, data was then exported to STAT A for analysis 
(STAT A, 2010). Data analysis examined both the pubettal trajectory and menstrual 
management of eligible cases. Pubettal trajectory was divided into three stages: the trajectory 
to Tanner stage two, trajectory to menarche and the trajectory between Tanner stage two and 
the onset of menarche. In examining issues relating to menstrual management issues 
petiaining to pubetiy and menstrual management were described and the frequency of 
menstrual suppression through medical and surgical techniques described. 
Pubertal Trajectory 
Tanner stage two was accepted as the first sign ofpubetty (Marshall & Tanner, 1969). At 
each wave parents were asked to score their daughter's level of breast development and pubic 
hair development based on a visual representation of the Tanner stages (Figure 1 and 2). 
Where stage two was not documented and the individual had progressed from stage one to 
stage three between waves, a mid-point between the two time points was imputed. Age at 
menarche was measured by parent's response to the question, "At what age did your daughter 
commence menstruation?" In cases where several ages were reported for menarche the first 
recording was taken. If an individual had not reached menstruation at one survey and the 
following survey stated they had reached menarche and no age was provided the midpoint 
between the two time points was imputed. 
The effect of Body Mass Index (BMI) and mutation type on all three trajectories was 
investigated. BMI z scores were calculated using Centres for Disease Control (CDC) nom1s 
(Kuczmarski & Flegal, 2000; Ogden et al., 2002). For individuals with a gastrostomy (n = 63) 
only BMI scores prior to the gastrostomy were used. BMI z scores were categorised into 
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underweight (<-1.99), nonnal (-1.99-1.99) and overweight (>1.99) (Kuczmarski & Flegal, 
2000). Mutation group was classified as C-terminal deletion, early truncation, p.R1 06W, 
p.R133C, p.R168X, p.R255X, p.R270X, p.R294X, p.R306C, T158M, large deletions, and 
others. Cases where the results of genetic testing had not been provided or were negative 
were grouped separately. 
Survival analysis was used to analyse the pubertal trajectory of cases. (Klein & 
Moeschberger). Survival time was taken as the age at which the event occurred and in those 
that were censored survival time was calculated as the age at the most recent questionnaire. In 
analysing the trajectory from Tanner stage two to menarche survival time was calculated as 
the length oftime between Tanner stage two and the onset of menarche, and in those 
censored it was calculated as the time from Tanner stage two to the age at the most recent 
questionnaire. The Kaplan Meier method and life tables were used to calculate the survival 
estimates (Hosmer, Lemeshow, & May, 2008). The relationships between BMI and mutation 
on the trajectories were investigated using Cox proportional hazards method (Allison; Klein 
& Moeschberger). 
Menstrual Management 
Management of menstruation was described in relation to three key areas: issues experienced 
in menstruation; medications taken to manage menstruation; and the use of surgery in 
managing menstruation. Cases for this analysis were only included if they had reached 
menarche. The following factors were examined: age, functional ability, presence of epilepsy, 
BMI and mutation type. BMI, mutation and age at most recent questionnaire were calculated 
the same way as they were in the analysis ofpube1ial trajectory. Functional ability was 
measured by a total WeeFIM score (Msall et al., 1994). The Wee FIM is a standardised 
assessment composed of 18 items in six domains which has been repmied to have excellent 
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test-re-test and inter-rater reliability and high criterion validity (Msall et al., 1996). The 
presence of epilepsy was collected in the medical conditions section of each questionnaire by 
parental response to the question, "Has your daughter ever been diagnosed with epilepsy?" 
Descriptive statistics and regression were used to describe the frequencies of use and types of 
menstrual suppressants and issues experienced and to make comparisons with specific 
factors. To add further detail to the descriptive statistics individual quotations from the open 
questions in the puberty section of the questionnaire were included. 
Methods Down syndrome 
The Down syndrome data for the cunent study was based on information collected in the 
Down Syndrome Needs Opinions and Wishes (NOW) questionnaire administered in 2004. 
The questionnaire was sent to 500 families of children and young people with Down 
syndrome aged up to 25 years, who were sourced through the Intellectual Disability 
Exploring Answers Database (Bourke et al., 2008). Individuals were included in the current 
study if they were female and their families had answered the puberty section of the 
questionnaire. Participants were only included if they were over the age of 12 as this was a 
specification on the questionnaire. 
Data Management and Analysis 
All data were de-identified and electronically stored at the Telethon Institute for Child Health 
Research. Data were cleaned and coded in Filemaker Pro and exported to STAT A for 
analysis (FileMaker, 2010; STATA, 2010). Analysis ofthe pube1ial trajectory in females 
with Down syndrome was divided into two sections; the trajectory to the first sign of puberty 
and the trajectory to menarche. Issues relating to menstrual management were examined in 
relation to the use of menstrual suppressants and the issues experienced in puberty. 
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Pubertal Trajectory 
The age at the first sign of pube1ty was taken from parent's response to the question, "Has 
your child begun to display signs of puberty? (Growth of pubic or hair breast budding)". 
Parents responding positively to this question were asked to indicate the age of their child 
when they first noticed theses changes. This age was then taken as the failure point for the 
trajectory to the first sign ofpube1ty. Age at menarche, in years and months, was obtained 
from response to the question, "Has your daughter started having menstrual periods; how old 
been your daughter when she stmted her periods?" Survival analysis was used to analyse the 
trajectory to both the commencement of pube1ty and menarche. In both trajectories survival 
time was calculated as the length of time from bilth to the event, in individuals who were 
censored the survival time was the age the individual was at the 2004 questionnaire. Kaplan 
Meier method and life tables were used to determine survival estimates; both trajectories 
were analysed against BMI z scores using Cox proportional hazards method. 
Menstrual Management 
Description of menstrual management was carried out as for Rett syndrome. The use of 
menstrual suppressants and issues experienced in puberty were investigated in relation to age, 
total WeeFIM scores, BMI z-scores, and presence of thyroid condition through regression. 
Descriptive statistics were again used to describe the frequencies of use and types of 
menstrual suppressants and issues experienced and to make comparisons with specific 
factors. Where relevant, quotations pertaining to the issues in puberty and the suppressants 
used were included. 
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Results Rett syndrome 
Trajectories to Tanner stage two in cases with Rett syndrome 
This sample comprised of (n = 221) individuals and on average cases were under analysis for 
9.98 years, range (2.81, 27.54). A qumier of cases had reached Tanner stage two by 9.14 
years, halfby age 11, and three quarters by the age of 12.65 years (see Figure 4 and Table 2). 
The most common age to reach Tanner stage two was between 11 and 12 years of age. The 
youngest age at which Tanner stage two occurred was between five and six years of age (n = 
2), nine individuals reached between six and seven years and 12% reached the event by the 
age of eight. The latest age for the onset of Tmmer stage two was 21 years of age (see table 
1). Weight was identified as a contributing factor (see Figure 5), with individuals classed as 
overweight reaching Tanner stage two at an earlier time than those classed as underweight 
(Hazard Ratio(HR) = 4.1 09, 95% Confidence Interval (CI = 1.94, 8.72). Mutation type was 
also found to effect the age at which Tanner stage two was reached with females with C-
terminal mutations, (HR = 1.56, 95% CI = 0.81, 2.99) and p.R106W, (HR = 1.6, 95% CI = 
0.62, 4.11) reaching this stage at an earlier age in comparison to the baseline (mutation 
negative). Subjects with mutations p.Rl33C, (HR = 0.70, 95%, CI = 0.35, 1.4) and p.Rl68X, 
(HR = 0.64, 95% CI = 0.32, 1.26) were found to reach at a later age (see Figure 6 and table 
3). 
Trajectory to menarche in cases with Rett syndrome 
320 cases were included in the survival analysis of trajectory to menarche with the most 
common age for commencement of menarche occurring between 11 and 12 years and the 
median age to the event was 14 years of age. The youngest onset of menarche was between 
eight and nine years of age and the latest onset of menarche was 23 years of age (see Figure 7 
and Table 4),. Individuals with lower BMI reached menarche at a significantly later age than 
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those catergorised as overweight (HR = 4.348, 95% CI = 1.69, 11.17) (see Figure 8). In 
comparison to the baseline (mutation negative) earlier age of onset of menarche was 
associated with individuals with C-terminal mutations, (HR = 2.15, 95% CI = 1.22, 3.80) 
early truncation, (HR = 2.18, 95% CI = 1.03, 4.61) mutation p.R294X, (HR = 1.01, 95% CI = 
0.52,1.94) and p.T158M., (HR = 1.13, 95% CI = 0.61, 2.07). Later age of onset was 
associated with individuals with the mutation p.R168X, (HR = 0.60, 95% CI = 0.3, 1.23) 
p.R255X, (HR = 0.64, 95% CI = 0.3, 1.35) and p.R133C, (HR = 1.37, 95% CI = 0.71, 2.64) 
(see Figure 9 and table 5). 
Trajectory between Tanner stage two and menarche in cases with Rett syndrome 
Survival analysis between Tam1er stage two and menarche (n = 150) (see Figure 10 and 
Table 6) identified the average time under analysis to be 2.97 years, with a range of 0.001-
12.06 years. A quarter of cases had progressed between these two stages in 1.7 years, 50% in 
3.4 years and 75% in 7.6 years. The most common duration between the two events was 3 
years (n = 73). Pictorial representation in the form of two-way scatter plots revealed a longer 
progression period between the two events in cases who reached Tanner stage two at an 
earlier age (see Figure 13). Individuals who were of normal weight (HR = 1.26, 95% CI = 
0.74, 2.15) or overweight (HR = 1.27, 95% CI = 0.43, 3.76) progressed between these two 
stages more rapidly compared with those who were underweight (see Figure 11). Individuals 
with mutations p.R306C (HR = 2.86, 95% CI = 0.82, 9.93) and p.R294X, (HR = 1.9, 95% CI 
= 0.78, 4.9) had a shorter period of time between the two events, and p.T158M, (HR = 0.50, 
95% CI = 0.18, 1.4), p.R270X, (HR = 0.48, 95% CI = 0.16, 1.41) and p.R255X, (HR = 0.7, 
95% CI = 0.24, 2.11) had a longer period of time than those with the baseline mutation 
(mutation negative) (see Figure 12 and table 7). 
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Management o[Menstruation in Rett svndr01ne 
One hundred and seventy two cases had reached menarche and were included in the 
investigation of menstrual management and related issues. Of these 73 (42%) used a form of 
menstrual suppressant the most common being the oral contraceptive pill (n = 41) (see Figure 
14) and secondly, Depot Medroxy progesterone acetate (DMPA) (n = 27). Linear regression 
revealed that WeeFIM scores were higher though not significantly for patients using a 
menstrual suppressant, average= 29.16 (± 12.11) (Odds Ratio(OR) = -0.01, 95% CI = -0.01, 
0.01, p = 0:323) compared to patients not using a suppressant, average= 31.31 (± 16.03). Age 
was also found to impact the use of menstrual suppressants with patients on suppressants 
being on average 1.3 years older than those not, although this difference was not significant 
(OR= 0.01, 95% CI = -0.001, 0.03, p = 0.09). Logistic regression identified that females with 
mutations p.R106W (OR= -0.57, 95% CI = -1.07, -0.07, p = 0.025) and p.R270X (OR= 
0.43, 95% CI = 0.08, 0.78, p = 0.017) were significantly more likely to use a menstrual 
suppressant. Mothers whose daughters were on some form of suppressant commented: 
"Our daughter is on the oral "Pill" continuously as her periods distressed her 
greatly; she seemed to be in great pain and was lethargic for two days at the 
beginning of her period. Her seizures much are worse at that time". 
"I asked my Dr at one stage about the injection that prevents her periods for 3 or 6 
months, but he would not give it to her as I did not have Government approval. So I 
give her Nurofen for the first 2 days and nights when she seems to have most 
discomfort. " 
"[She 1 had DMPA injections for at least 2 years. When we heard about the story of a 
girl with osteo we took her off [She 1 has had only three intermittent periods after that 
then none since a year. Then she had a heavy period this week" 
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Exploration of these issues experienced in relation to menstruation revealed increased seizure 
activity to be the most commonly occmTing problem (n =51). Mothers whose daughters 
experienced problems with seizures during menstruation commented: 
"Seizure activity definitely increased at the onset of her periods. Bleeding was 
very heavy and due to inability to gauge her discomfort we decided to place her 
on the pill continuously to avoid this problem". 
"Seizures become more fi'equent with the onset of puberty. I have chosen not to 
manage menstruation and she is on the pill. " 
"Seizure activity definitely increased at the onset of her periods. Bleeding was very 
heavy and due to inability to gauge her discomfort decided to place her on the pill 
continuously to avoid this problem. If breakthrough bleeding occurs I allow her to 
have a period- approximately every 6 months. " 
Parents described other common issues associated with menstruation to include pain (n = 48), 
inegularity (n = 37), and heavy bleeding (n = 27) (see Figure 15). Comparisons between 
patients experiencing and those not experiencing issues identified that there was no 
significant association between subjects with issues and WeeFIM scores (OR= -0.00, 95% 
CI = -0.003, 0.003, p = 0.815), age (OR= -0.01, 95% CI = -0.2, 0.001, p = 0.091), or epilepsy 
(OR= 0.09, 95% CI = -0.04, 0.22, p = 0.153), 
Five of the 172 subjects had undergone surgery to eliminate menstruation; individuals who 
underwent this surgery were aged 10, 11, 11, 14 and 16. Logistic regression identified that 
none of the variables had a significant impact on the use of eliminating surgery. One mother 
whose daughter's had a hysterectomy commented: 
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"This surge1y was undergone solely for her comfort. Mother stiffered severe pain, 
nausea all her reproductive years, when menstruating and didn't vvant daughter to 
stiffer similarly". 
Results Down syndrome 
Pubertal Trajectory in Down syndrome 
The dataset for the trajectory to the first sign of puberty in females over 12 years with Down 
syndrome comprised 66 individuals. The average time under analysis for individuals in this 
analysis was 12 years. The median age for puberty and menarche for individuals with Down 
syndrome was 12 years (see Figure 16 and Table 10). BMI impacted on age at puberty with 
higher BMI resulting in earlier onset (HR = 1.169, 95% CI = 0.85, 1.61). The trajectory to 
menarche utilised the same data set (n = 66) and the average time under analysis for the 
trajectory to menarche was 12.64 years and the median age to the event was 12.3 years (see 
Figure 17 and Table 11 ). The most common age at commencement of menarche was between 
12 and 13 years of age (n = 23). Analysis for the relationship between BMI and age at 
menarche identified the risk of menarche to increase as BMI increased (HR = 1.89, 95% CI = 
0.90, 1.57). 
Menstrual Management in Down syndrome 
All females over 12 years who had reached menarche were included in the investigation of 
menstrual management (n = 60). Of these 14 (23.33%) used a menstrual suppressant. Nearly 
half (43%) of those using a suppressant had a thyroid condition. Individuals using a 
menstrual suppressant were on average 1.18 years older than those not using a suppressant. 
The most commonly used suppressant was the oral contraceptive pill (n = 9) followed by 
DMPA (n = 2) (see Figure 18). Regression identified that; Wee FIM (OR= -0.01, 95% CI =-
0.01, 0.002, p = 0.163); epilepsy (OR= 0.12, 95% CI = -0.59, 0.83, p = 0.735); thyroid 
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condition (OR= 0.23, 95% CI = -0.04, 0.49, p = 0.096), and age (OR= 0.02, 95% CI = -
0.01, 0.06, p = 0.201) did not have a significant impact on whether or not individuals with 
Down syndrome used a menstmal suppressant. No parents of daughters with Down syndrome 
repmied that their daughter had undergone surgery to eliminate menstmation. One mother 
whose daughter had previously used the oral contraceptive pill stated: 
"Heavy bleeding was a problem, after 2 years we tried the contraceptive pill with 
some success but this caused a deep vein thrombosis (DVT) problem at the age of 
20y~ars. As a result we have a lifelong problem and can no longer use the pill. 
Medication for blood thinning is permanent. We have subsequently had an IUD 
inserted with tremendous success. A definite improvement in quality of life for a 
young woman who really finds her period a great inconvenience. " 
One mother whose daughter was not using any fonn of menstmal suppressant stated: 
"I don't believe in children with disabilities having to take medication unless really 
necessary" 
Categorisation of the issues experienced in puberty identified the most common issue to be 
daughter's understanding of what was going on (n = 18) (See Figure 19). This finding was 
reflected through numerous mothers' comments which highlight some of the 
misunderstandings .. 
"I thought I had done a good job of explaining 'the facts of life' in simple and 
understandable terms for my daughter however, when her first period arrived I was 
horrified to realise she thought she was 'having a baby' ... so much for my expertise of 
explaining! We survived of course but I realised how difficult it was to be sure she 
'understood' what was taking place with 'details on many issues". 
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"[She] did not understand the appropriate behaviour and was easily persuaded into 
overt sexual behaviour by other normal teenagers e.g. kissing boys despite education 
to the contrary. [She J became socially withdrawn during puberty. This may be due to 
the teasing and rejection by other teens during these years. [She] was very outgoing, 
happy and accepted by pears prior to puberty". 
"My daughter has to be protected from sexual exploitation as she could be taken 
advantage of easily. This restricts her independence" 
Of the 60 females included in this analysis 90% repmied experiencing an issue. 
Experiencing an issue was associated with higher BMI z-scores 1.03 (±0.89) compared to 
0.88 (±0.54). Age was also found to be different with the average age of those experiencing 
issues being 18.70 (±3.42) compared to 15.88 (±2.97) in those with no issues. Regression 
identified that none of these changes was significant. 
Discussion 
This study aimed to describe the pube1ial trajectory in females with Rett syndrome and Down 
syndrome. In addition it explored the management of menstruation within these two 
populations. 
It was found that in females with Rett syndrome the median age at which individuals reached 
Tanner stage two was 11 years. In females with Down syndrome the most common age to 
Tanner stage two, was one year later than in Rett syndrome with the median age being 12 
years. American Research examining the onset of pube1iy in the normative population has 
reported the average age of thelarche (onset of breast development) in Caucasians to be 10 
years and in African American females it was one year earlier. Onset ofpubarche was found 
to be 10.5 and 9 years of age in Caucasians and African American females, respectively 
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(Herman-Giddens, 2006). These findings suggest that the onset ofpube1ty may be delayed in 
females with Rett syndrome and Down syndrome. A wide range was identified in the 
trajectory to Tanner stage two in Rett syndrome with the earliest onset being five to six years 
of age and the latest being 21 years of age. Both these findings fall significantly outside the 
pubertal norms suggesting pubertal trajectory in females with Rett syndrome is abnormal. 
The median age to reach menarche in females with Rett syndrome was 14 years of age with 
the most common age to reach being 11-12 years. These findings are similar to those reported 
in Holm's 1986 study comprising of 21 females with Rett syndrome, Holm's study 
documented the average age of menarche in to be 11.2 years, limitations of Holm's study 
were the small sample size used and as the identification of mutations in the MECP2 gene 
had not yet been discovered this study was unable to explore the effect of genotype (Holm, 
1986). In this sample of females with Rett syndrome the earliest onset of menarche was 
between eight and nine years of age and the latest was 23 years of age; pube1iy is classed as 
delayed if menarche has not been reached by the age of 16 (Shah, 1997). The finding of 
menarche occmring at 23 years of age fmiher suggests that pubertal trajectory may be 
abnmmal in females with Rett syndrome. In females with Down syndrome the most common 
age to reach menarche was 12 to 13 years with the median age being12.3 years. These 
findings are similar to those of Scola, Seigfried & Pueschel (1992) and Arnell, Gustafasson, 
Ivarsson & Anneren (1996) studies, which reported the average age of menarche to be 13.2 
years, range (11.8-16.2) and 12.6 years, range (10-16), respectively. Findings regarding 
puberty in the normative sample of Americans were described through the National Health 
and Nutrition Examination Survey (NHANES) study which identified the average age of 
menarche to be 12.6 years in Caucasians and 12.1 years in coloured females, both ofwhich 
are similar to the findings in the current study (Herman-Giddens, 2006). 
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Examination of the trajectory between Tanner stage two and menarche in females with Rett 
syndrome revealed that half of the subjects progressed between the two stages in 3.4 years, 
with the most common duration between the two events being 2-3 years. It was found that 
those who reached Tmmer stage two at an earlier age took a longer period of time to reach 
menarche. The study of Marti-Henneberg and Vizmanos (Marti-Henneberg & vizmanos, 
1997) based on the normative population rep01ied a shorter time frame between the two 
events with an average age of 1.96 years± 0.06. This study also identified that the timing of 
onset of Tanner stage two influenced the duration between the onset and menarche, with 
those commencing puberty at an earlier age taking a longer length of time between the two 
events. 
Body weight was found to impact on pube1ial trajectory in both females with Rett syndrome 
and Down syndrome, with higher BMI scores associated with earlier onset of puberty and 
menarche and a sh01ier duration between these two stages. These findings concur with 
previous population based research in the normative population which rep01ied a strong 
relationship between higher BMI' s and earlier onsets of puberty (Anderson, Dallal, & Must, 
2003; Lin-Su, Vogiatzi, & New, 2002).Pubertal trajectory in Rett syndrome was analysed in 
relation to genotype, revealing the greatest impact to be the trajectory between Tanners stage 
two and menarche. Cases with mutation R270X and R255X were found to take the greatest 
length of time to progress between these two stages. Australian population based research 
exploring the genotype phenotype relationship in Rett syndrome have identified that cases 
with these mutations to have the most severe phenotype (Bebbington et al., 2008; Colvin et 
al., 2003; Colvin et al., 2004; H. Leonard et al., 2003). 
Analysis of menstrual management in females with Rett syndrome and Down syndrome 
found oral contraceptive pills to be the most frequently used method of menstrual suppressant 
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followed by DMP A. In females with Rett syndrome the most common issue experienced was 
increased seizure activity, whereas in Down syndrome it was lack of understanding. Mother's 
comments in both Rett syndrome and Down syndrome highlighted numerous issues 
experienced in pube1iy. Functional ability, BMI, age of epilepsy onset and the presence of a 
thyroid condition had very little effect on the menstrual suppressants used and issues 
experienced in both Rett syndrome and Down syndrome. Similar findings were reported in a 
study conducted in Brussels (n = 397) which explored the use of suppression and elimination 
in females with a mild to profound intellectual disability finding 22.2% of cases were 
sterilised, 18% used OCP and 17.6% used DMPA (Servais et al., 2002). The identification of 
lack of understanding which was reported as the most frequently occUlTing issue in females 
with Down syndrome is suppmied in previous research into intellectual disability which 
identified that this population does not receive adequate education leading up to the onset of 
puberty (Lin & Barnhart, 2007; McEvoy, Chang, & Coupey, 2004). 
In interpreting the findings from this study several limitations should be considered. The data 
collection method through surveys resulted in the possibility of recall enor where parents or 
carers provided inconect answers due to memory recall over time. In the Rett syndrome 
questionnaires parents were asked to document their daughters Tanner stage however were 
not asked the specific age at which the stage occuned. The main limitation of the study was 
that in the Down syndrome NOW questionnaire parents were only asked to answer the 
puberty section if their daughter was over the age of 12, which may have resulted in the loss 
of valuable information. Although limitations exist, this study has many strengths and 
provides valuable insight into puberty within these two populations. This study is unique as it 
describes the trajectory through pube1iy along with genotype and BMI which has to our 
knowledge never been studied before. 
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The information reported in this study is valuable for parents, carers, health care 
professionals and educators as it highlights the trajectory through puberty and in the 
management of menstruation it highlights what menstrual suppressants are being used and the 
issues experienced. This is valuable information as many menstrual suppressants have been 
found to have serious health consequences such as deep vein thrombosis, osteopenia and 
other bone dysmorphologies (H. Leonard, et al., 1995; H. Leonard, Thomson, Glasson, Fyfe, 
Leonard, Bower, et al., 1999; H. Leonard, Thomson, Glasson, Fyfe, Leonard, Ellaway, et al., 
1999; Watson, Lentz, & Cain, 2006)For health professionals this study highlights the need for 
education programmes or interventions to be run for the individuals and their parents to best 
prepare them for this challenging transition in life. 
Occupational therapists could assist individuals with intellectual disabilities and their families 
through this transition, by running education groups to prepare both the individual and their 
families of what to expect, provide recourses relating to menstrual suppressants, 
contraceptives and strategies in managing menstruation. As mentioned earlier the side effects 
associated with many of the suppressants have series health consequences for the individuals, 
as part of a multidisciplinary team Occupational therapist could assist in informing parents of 
the options available and there advantages and disadvantages. 
To our knowledge this is the first study to explore pubertal trajectory and management of 
menstruation in females with Rett syndrome and Down syndrome. To further assist 
individuals in these populations and expand health care professionals knowledge in the area 
further population based longitudinal research is needed. 
Puberty 73 
References 
Allison, P. D. Survival Analysis using SAS: A practice Guide. USA: SAS Institute Inc. 
Amir, R. E., VanDer Veyver, I. B., Wan, M., Tran, C. Q., Francke, U., & Zoghbi, H. U. 
(1999). Rett syndrome is caused by mutations in x-linked MECP2 encoding methyl-
CpG-binding protien 2. Nature Genetics, 23, 185-188. 
Anderson, S., E, Dallal, G., E, & Must, A. (2003). Relative weight and race influence average 
age at menarche: Results from two nationally representative surveys of US girls 
studied 25 year appart. Journal of the American Academy of Pediatrics 111(4), 844-
849. 
Arnell, H., Gustafasson, J., Ivarsson, S. A., & Anneren, G. (1996). Growth and pube1ial 
development in Down Syndrome. Acta Paediatrics, 85, 1102-1106. 
Bebbington, A., Anderson, A., Ravine, D., Fyfe, S., Pineda, M., Klerk, N., et al. (2008). 
Investigating the genotype phenotype relationship in Rett syndrome using an 
international data set. Neurology, 70(868-875). 
Bourke, J., Ricciardo, B., Aiberti, K., Jacoby, P., Dyke, P., Msall, M., et al. (2008). Physical 
and mental health in mothers of children with Down syndrome The Journal of 
Paediatrics, 153(3), 320-326. 
Bower, C., Rudy, E., Callaghan, A., Quick, J., Cosgrove, P., & Nassar, N. (2009). Reports of 
the birth defects registry of Western Australia. 
Colvin, L., Fyfe, S., Leonard, H., Schiavello, S., Ellaway, C., Klerk, N., et al. (2003). 
Describing the phenotype in Rett syndrome using a population database. Archives of 
Disability and Childhood, 88, 38-43. 
Puberty 74 
Colvin, L., Leonard, H., Klerk, N., Weaving, L., Davis, M., Williamson, S., et al. (2004). 
Refining the phenotype of common mutations in Rett syndrome. Journal of Medical 
Genetics, 41, 25-30. 
Denzer, C., Weibel, A., Muche, R., Karges, B., Sorgo, W., & Wabitsch, M. (2007). Pubertal 
development in obese children and adolescents. International Journal of Obesity, 31, 
1509-1519. 
Ellis, B. J. (2004). Timing of pubertal maturation in girls: An intergrated life history 
approach. Psychological Bulletin, 130(6), 920-958. 
FileMaker. (2010). FileMaker Retrieved 7th October, 2010, from http:/hvww.filemaker.com/ 
Gibson, P., Newton, R., Selby, K., Price, D., Leyland, K., & Addison, G. (2005). 
Longitudinal study of thyroid function in Down syndrome in the first two decades. 
Archives of Disability and Childhood, 90, 574-578. 
Hawli, Y., Nasrallah, M., & Fuleihan, G. (2009). Endocrine and musculoskeletal 
abnormalities in patients with Down syndrome. Endocrinology, 5, 327-334. 
Herman-Giddens, M. (2006). Recent data on pube1ial milestones in United States children: 
the secular trend toward earlier development. International Journal of Andrology, 29, 
241-246. 
Holm, V. A. (1986). Physical growth and development in patients with Rett syndrome. 
American Journal of Medical Genetics, 24, 119-126. 
Hosmer, D., Lemeshow, S., & May, S. (2008). Applied Survival Analysis (2 ed.). Canada: 
John Wiley &Sons. 
Huppke, P., Roth, C., Christen, H., Brockmann, K., & Hanefeld, F. (2001). Endocrinological 
study on growth retardation in Rett syndrome. Acta Paediatrics, 90, 1257-1261. 
Kaplowitz, P., B. (2008). Linlc between body fat and the timing of puberty. Pediatrics, 121, 
208-217. 
Pubeliy 75 
Klein, J. P., & Moeschberger, M. L. Survival Analysis: Techniques for Censored and 
Truncated Data. USA: Springer. 
Kuczmarski, R., & Flegal, K. (2000). Criteria for defenition of overweight in transition: 
background and recommendations for the United States. Am J Clin Nutr, 72, 1074-
1081. 
Laurvick, C., L, Klerk, N., Bower, C., Christodoulou, J., Ravine, D., Ellaway, C., et al. 
(2006). Rett syndrome in Australia: A review of the epidemiology. The Journal of 
Pediatrics, 148, 347-352. 
Leonard, H., Bower, C., & English, D. (1997). The prevelance and incidence ofRett 
syndrome in Australia. European Child & Adolescent Psychiatry, 6, 8-10. 
Leonard, H., Bower, C., & English, D. (1997). The prevelance and incidence ofRett 
syndrome in Australia. European Child and Adolescent Psychiafly, 6, 8-10. 
Leonard, H., Colvin, L., Christodoulou, J., Schiavello, S., Williamson, S., Davis, M., et al. 
(2003). Patients with the R133C mutation: is their phenotype different from patients 
with Rett syndrome with other mutations. Journal of Medical Genetics, 40, 1-7. 
Leonard, H., Thomson, M., Bower, C., Fyfe, S., & Constantinou, J. (1995). Skeletal 
abnormalities in Rett syndrome: Increasing evidence for dysmorphogenetic defects. 
American Journal of Medical Genetics, 58, 282-285. 
Leonard, H., Thomson, M., Glasson, E., Fyfe, S., Leonard, S., Bower, C., et al. (1999). A 
population based approach to the investigation of osteopenia in Rett syndrome. 
Developmental Medicine & Cjild Neurology, 41, 323-328. 
Leonard, H., Thomson, M., Glasson, E., Fyfe, S., Leonard, S., Ellaway, C., et al. (1999). 
Metacarpophalangeal pattem profile and bone age in Rett syndrome: Fuliher 
radiological clues to the diagnosis. American Journal of Medical Genetics, 83, 88-95. 
Pube1iy 76 
Leonard, S., Bower, C., Petterson, B., & Leonard, H. (2000). Survival of infants bom with 
with Down syndrome. Paediatric and Perinatal Epidemiology, 14, 163-171. 
Lin-Su, K., Vogiatzi, M., & New, M. (2002). Body mass index and age at menarche in an 
adolescent clinic population. Clinical Pediatrics, 41(7), 501-506. 
Lin, K., & Barnhart, K. (2007). The clinical rational for menses free contracteption. Journal 
ofWomen's Health, 16(8), 1171-1180. 
Marshall, W., A, & Tam1er, J., M. (1969). Variations in pattem ofpube1ial changes in girls. 
Archives of Disease in Childhood, 44, 291-303. 
Mmii-Henneberg, C., & vizmanos, B. (1997). The duration ofpube1iy in girls is related to the 
timing of its onset. The Journal of Pediatrics, 131(4), 618-621. 
McEvoy, M., Chang, J., & Coupey, S. (2004). Common menstrual disorders in adolescence. 
Nursing Interventions, 29(1 ), 41-49. 
Mount, R. H., Hastings, R. P., Reily, S., Cass, S., & Charman, T. (2001). Behavioural and 
emotional features in Rett syndrome. Disability and Rehabilitation, 23(3/4), 129-138. 
Msall, M., E, DiGaudio, K., Rodgers, B., T, LaForest, S., Catanzaro, N., L, Campbell, J., et 
al. (1994). The functional independance measure for children (WeeFIM). Clinical 
Pediatrics, 33, 421-430. 
Msall, M., E, Ottenbacher, K., Duffy, L., Lyon, N., Heya, N., Phillips, L., et al. (1996). 
Reliability and validity of the WeeFim in children with neurodevelopmental 
disabilities. Pediatric Research, 39, 2251. 
Neul, J., L. (2008). Specific mutations in Methyl-CpG-Binding Protien 2 confer different 
severity in Rett syndrome. Neurology, 70(16), 1313. 
Nosek, M., A, Foley, C., C, Hughes, R., B, & Howland, C., A. (2001). Vulnerabilities for 
abuse among women with disabilities. Sexuality and Disability, 19(3), 177-189. 
Pube1iy 77 
Ogden, C., Kuczmarski, R., Flegal, K., Mei, Z., Guo, S., Wei, R., et al. (2002). Centres for 
Disease Control and Prevention 2000 growth chmis for the United States: 
Improvements to the 1977 National Centre for Health Statistics version. Official 
Journal of the American Academy of Pediatrics, 1 09(1 ), 45-60. 
Onland-Moret, N., Peeters, P., Van Gills, C., Clavel-Chapelon, F., Key, T., Tjom1eland, A., et 
al. (2005). Age at menarche in relation to adult height. American Journal of 
Epidemiology, 162(7), 624-632. 
Petterson, B., Leonard, H., Bourke, J., Sanders, R., Chalmers, R., Jacoby, P., et al. (2005). 
Idea intellectual disability exploring answers: A population-based database for 
intellectual disability in Australia. Annals of Human Biology, 32(2), 237-243. 
Plant, T., & Barker-Gibb, M. (2004). Neurobiological mechanisms ofpubeliy in higher 
primates. Human Reproduction Update, 10(1), 67-77. 
Prasher, V., & Gomez, G. (2007). Natural history ofthyroid dysfunction in adults with Down 
syndrome - 10 year follow up study. 
Scola, P. S., Siegfried, M., & Pueschel, M.D. (1992). Menstrual cycles and basal body 
temperature curves in woman with Down syndrome. Obstetrics &Gynecology, 79(1 ), 
91-93. 
Servais, L., Jaques, D., Leach, R., Conod, L., Hoyois, P., Dan, B., et al. (2002). 
Contraception for women with intellectual disability: prevelance and determinants. 
Journal of Intellectual Disability Research, 46(2), 108-119. 
Shah, N. (1997). Delayed pubeliy. Indian Journal of Pediatrics, 64, 159-164. 
STAT A. (2010). Data Analysis and Statistical Software Retrieved 7th October, 2010, from 
http:/ /www.stata.com/ 
Terasawa, E., & Fernandez, D. (2001). Neurobiological mechanisms of the onset ofpubeliy 
in primates. Endocrine Reviews, 22, 111-151. 
Puberty 78 
Watson, K., Lentz, M., & Cain, K. (2006). Associations between fracture incidence and use 
of depot medroxyprogesterone acetate and antiepileptic drugs in women with 
developmental disabilities. Women's Health Issue, 16, 346-352. 
Pube1iy 79 
Figures 
Puberty 80 
Figure 4 
Kaplan Meier Graph, the trajectory to Tanner stage two in Rett syndrome 
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Kaplan Meier Graph, Effect of BMI on the trajectmy to Tanner stage two in Rett syndrome 
0 q 
L/") 
....... 
d 
0 
L/") 
d 
If) 
N 
d 
0 
0 
d 
Kaplan-Meier survival estimates (Tanners stage 2 and BMI) 
0 10 20 30 
--- GRP _BMI = Underweight --- GRP _BMI = Normal 
--- GRP _BMI = Overweight 
Figure 6 
The relationship betvveen Tanner stage two and mutaNon 
Tanners Stage Two and Mutation 
4 
3 
2 
T T 4 4 4 ~ 
4 t t ~ 
0 
Mutation 
I• Hazard Ratio 
--- 95%CI> 
Figure 7 
Kaplan Me ier Graph, the traj ectmy to Tanner stage two in Rett syndrome 
0 
C? 
..... 
1./') 
"" c:i
0 
1./') 
c:i 
1./') 
N 
c:i 
0 
0 
c:i 
0 
Kaplan-Meier survival estimate (Menarche) 
10 20 
Age (years) 
Puberty 81 
30 
Puberty 82 
Figure 8 
Kaplan Meier Graph, Effect of BMI on the trajectory to Menarche in Rett syndrome 
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Kaplan-Meier survival estimates (Menarche and BMI) 
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Figure 10 
Kaplan Meier Graph, the trajectory betlveen Tanner stage two and menarche in Rett 
syndrome 
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Figure 11 
Kaplan Meier Graph, Effect of BMI on the trajectmy between Tanner stage tlVo and 
menarche in Rett syndrome 
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Figure 12 
The relationship beh-veen the Trajectmy from Tanner stage h1'0 to Menarche and mutation 
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The relationship bern;een Tanner stage h-vo and Menarche 
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The use of menstrual suppressants in females with Rett syndrome 
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The issues experienced in puberty in females with Rett syndrome 
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Figure 16 
Kaplan Me;er Graph, the trajectory to the first sign of puberty ;n Down syndrome 
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Kaplan Mder Graph, the trajectory to menarche in Down syndrome 
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The use ofmenstrual suppressants ;njemales wUh Down syndrome 
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Table 2 
Life Table to Tanners Stage Two 
Interval! Beg Total Failure a Censored b Survival SE 95% conf. Int 
2 3 221 0 2 1 1 
3 4 219 0 6 1 1 
4 5 213 0 14 1 
5 6 199 2 9 0.99 0.01 0.96 1.00 
6 7 188 9 5 0.94 0.02 0.90 0.97 
7 8 174 12 3 0.88 0.02 0.82 0.92 
8 9 159 21 6 0.76 0.03 0.69 0.81 
9 10 132 17 5 0.66 0.04 0.58 0.72 
10 11 110 23 5 0.52 0.04 0.44 0.59 
11 12 82 26 2 0.35 0.04 0.28 0.42 
12 13 54 23 2 0.20 0.03 0.14 0.26 
13 14 29 8 1 0.14 0.03 0.09 0.20 
14 15 20 3 1 0.12 0.03 0.07 0.18 
15 16 16 3 0 0.10 0.02 0.06 0.15 
16 17 13 2 0 0.08 0.02 0.05 0.13 
17 18 11 1 0 0.08 0.02 0.04 0.13 
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Life Tables to Tanner stage tlvo continued 
Interval! Beg Total Failure a Censored b survival std enor 95% conf. Int 
18 19 10 1 1 0.07 0.02 0.03 0.12 
19 20 8 2 0 0.05 0.02 0.02 0.10 
21 22 ?" 6 1 0 0.04 0.02 0.02 0.09 
22 23 5 0 1 0.04 0.02 0.02 0.09 
24 25 4 0 1 0.04 0.02 0.02 0.09 
25 26 3 0 1 0.04 0.02 0.02 0.09 
a Refers to the onset of Tanner stage two 
b Refers to the individuals who died or withdrew from the study 
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Table 3 
Cox Proportional Hazards Ratio; Genotype and Trajectory to Tanner stage two 
-t HRa z p>[z] [95% conf. Interval 
C-terminal 1.56 0.52 1.34 0.180 0.81 2.99 
Early truncation 0.80 0.39 -0.46 0.646 0.31 2.06 
Not tested 0.81 0.32 -0.53 0.595 0.37 1.76 
Other 1.02 0.29 0.05 0.957 0.58 1.79 
p.R106W 1.60 0.77 0.97 0.334 0.62 4.11 
p.R133c 0.70 0.25 -1.01 0.313 0.35 1.40 
p.R168X 0.64 0.22 -1.29 0.197 0.32 1.26 
p.R255X 0.91 0.41 -0.21 0.831 0.38 2.18 
p.R270X 1.17 0.44 0.41 0.684 0.55 2.46 
p.R294X 0.81 0.32 -0.54 0.586 0.37 1.75 
p.R306C 0.84 0.38 -0.39 0.700 0.35 2.02 
p.T158M 1.33 0.45 0.84 0.402 0.68 2.60 
Uncettain 0.60 0.61 -0.51 0.613 0.08 4.39 
Larger deletion 1.47 0.59 0.97 0.332 0.67 3.21 
a Refers to Hazards Ratio 
b Refers to Standard Error 
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Table 4 
Life table and Menarche 
Interval Beg Total Failure a Censored b Survival SE 9 5% con f. Int 
2 3 320 0 2 1 0 
3 4 318 0 7 1 0 
4 5 311 0 16 1 0 
5 6 295 0 10 1 0 
6 7 285 0 7 1 0 
7 8 278 0 5 1 0 
8 9 273 1 17 1.00 0.00 0.97 1.00 
9 10 255 6 9 0.97 0.01 0.94 0.99 
10 11 240 14 15 0.91 0.02 0.87 0.94 
11 12 211 31 9 0.78 0.03 0.72 0.82 
12 13 171 27 12 0.65 0.03 0.58 0.71 
13 14 132 23 4 0.53 0.03 0.47 0.60 
14 15 105 24 6 0.41 0.03 0.34 0.48 
15 16 75 16 7 0.32 0.03 0.25 0.38 
16 17 52 16 4 0.22 0.03 0.16 0.28 
17 18 32 7 6 0.16 0.03 0.11 0.22 
18 19 19 3 2 0.14 0.03 0.09 0.20 
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Life Tables to Menarche stage two continued 
Interval Beg Total Failure a Censored b Survival SE 95% conf. Int 
19 20 14 3 2 0.10 0.03 0.06 0.16 
20 21 9 1 1 0.09 0.03 0.05 0.15 
22 23 7 2 1 0.06 0.02 0.03 0.12 
23 24 4 1 0 0.05 0.02 0.02 0.11 
25 26 3 0 1 0.05 0.02 0.02 0.11 
26 27 2 0 1 0.05 0.02 0.02 0.11 
a Refers to the onset of Menarche 
b Refers to the individuals who died or withdrew from the study 
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Table 5 
Cox Proportional Hazards Ratio,· Genotype and Trajectory to menarche 
-t HRa SEb z p>[z] [95% conf. Interval 
C-terminal 2.16 0.62 2.65 0.008 1.22 3.80 
Early truncation 2.18 0.83 2.03 0.042 1.03 4.61 
Other 1.13 0.33 0.43 0.666 0.64 1.99 
p.R106W 1.06 0.56 0.11 0.913 0.38 2.96 
p.R133c 1.37 0.46 0.95 0.343 0.71 2.64 
p.R168X 0.60 0.22 -1.39 0.166 0.30 1.23 
p.R255X 0.64 0.24 -1.18 0.238 0.30 1.35 
p.R270X 0.60 0.21 -1.48 0.138 0.30 1.18 
p.R294X 1.01 0.34 0.03 0.979 0.52 1.94 
p.R306C 1.98 0.72 1.87 0.061 0.97 4.04 
p.T158M 1.13 0.35 0.38 0.704 0.61 2.07 
Uncertain 1.67 1.00 0.86 0.389 0.52 5.37 
Larger deletion 0.56 0.26 -125 0.212 0.22 1.40 
a Refers to Hazards Ration 
b Refers to Standard Error 
Table 6 
Life table and Tanners stage two-Menarche 
Interval a Beg Total Failure b 
0 1 150 
1 2 130 
2 3 73 
3 4 55 
4 5 38 
5 6 23 
6 7 19 
7 8 14 
8 9 8 
9 10 6 
10 11 3 
11 12 2 
12 13 1 
• Interval refers to the period of time in years 
b Refers to the onset of Menarche 
19 
22 
12 
11 
9 
3 
1 
2 
1 
1 
1 
1 
0 
Censored c 
1 
35 
6 
6 
6 
1 
4 
4 
1 
2 
0 
0 
1 
c Refers to the individuals who died or withdrew from the study 
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Survival SE 95% conf. Int 
0.87 0.03 0.81 0.92 
0.70 0.04 0.62 0.77 
0.58 0.05 0.49 0.66 
0.46 0.05 0.36 0.55 
0.34 0.05 0.25 0.44 
0.30 0.05 0.20 0.39 
0.28 0.05 0.19 0.38 
0.23 0.05 0.14 0.34 
0.20 0.06 0.11 0.31 
0.16 0.06 0.07 0.28 
0.11 0.06 0.03 0.25 
0.05 0.05 0.01 0.20 
0.05 0.05 0.01 0.20 
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Table 7 
Cox Proportional Hazards Ratio; Genotype and Trajectory benveen Tanner stage Two and 
menarche 
-t HRa SEb z p>[z] [95% conf. Interval 
C-terminal 1.82 0.74 1.46 0.144 0.82 4.06 
Early truncation 1.78 1.12 0.92 0.358 0.52 6.08 
Not tested 0.85 0.48 -0.29 0.769 0.28 2.58 
Other 1.45 0.54 1.01 0.313 0.70 3.01 
p.R106W 1.24 1.29 0.21 0.834 0.16 9.47 
p.R133c 1.07 0.59 0.13 0.900 0.36 3.17 
p.R168X 0.57 0.31 -1.02 0.307 0.19 1.68 
p.R255X 0.71 0.39 -0.62 0.535 0.24 2.11 
p.R270X 0.48 0.26 -1.33 0.182 0.16 1.41 
p.R294X 1.97 0.93 1.43 0.154 0.78 4.98 
p.R306C 2.86 1.82 1.65 0.098 0.82 9.93 
p.T158M 0.50 0.26 -1.32 0.187 0.19 1.40 
Uncertain 0.60 0.62 -0.49 0.622 0.62 4.52 
Larger deletion 0.37 0.21 -178 0.076 0.08 1.11 
a Refers to Hazards Ration 
b Refers to Standard Error 
Table 8 
Rett syndrome and menstrual suppressants 
Suppressant 
Depot Medroxy Progesterone Acetate 
Mirena Intrauterine Device 
Kliovance 
Oral Contraceptive Pill 
Table 9 
Rett syndrome and issues experienced in puberty 
Issue 
Painful 
Irritable 
Irregular 
Heavy 
Seizure 
Number of people 
Number of people 
27 
4 
1 
41 
48 
31 
37 
27 
51 
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Percentage 
15.7 
2.33 
0.58 
23.84 
Percentage 
27.9 
18.02 
21.51 
15.7 
29.7 
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Table 10 
Life table and Down syndrome Puberty 
Interval Beg Total Failure a Censoredb Survival SE 95% conf. Int 
8 9 66 2 0 0.9697 0.0211 0.8842 0.9923 
9 10 64 1 0 0.9545 0.0256 0.8657 0.9851 
10 11 63 9 0 0.8182 0.0475 0.7021 0.8924 
11 12 54 10 0 0.6667 0.058 0.5393 0.7663 
12 13 44 16 2 0.4186 0.0612 0.2982 0.5343 
13 14 26 7 0 0.3059 0.0577 0.1983 0.4202 
14 15 19 5 3 0.2185 0.0528 0.1254 0.3282 
15 16 11 1 2 0.1967 0.0518 0.107 0.3062 
17 18 8 0 1 0.1967 0.0518 0.107 0.3062 
19 20 7 0 1 0.1967 0.0518 0.107 0.3062 
• Refers to the onset of puberty 
b Refers to the individuals who died or withdrew from the study 
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Table 11 
Life table and Down syndrome Menarche 
Interval Beg Total Failure a Censoredb Survival SE 95% conf. Int 
9 10 66 1 0 0.9848 0.0150 0.8973 0.9979 
10 11 65 3 0 0.9394 0.0294 0.8465 0.9768 
11 12 62 13 0 0.7424 0.0538 0.6188 0.8312 
12 13 49 23 1 0.3903 0.0603 0.2731 0.5057 
13 14 25 14 2 0.1626 0.0466 0.0842 0.2637 
14 15 9 4 2 0.0813 0.0370 0.0279 0.1723 
15 16 3 1 0 0.0542 0.0331 0.0123 0.1448 
16 17 2 1 0 0.0271 0.0253 0.0025 0.1140 
23 24 1 0 1 0.0271 0.0253 0.0025 0.1140 
a Refers to the onset of Menarche 
b Refers to the individuals who died or withdrew from the study 
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Table 12 
Down syndrome and Menstrual suppressants 
Suppressant Number of people Percentage 
Depot Medroxy Progesterone Acetate 2 8.7 
Mirena Intrauterine Device 1 4.3 
Mini IUD 2 8.7 
Oral Cont\aceptive Pill 9 39.1 
Table 13 
Down syndrome and the issues experienced in puberty 
Issue Number of people Percentage 
Inappropriate 8 14.8 
Painful 11 20.4 
Irregular 6 11.1 
Heavy 8 14.8 
Understanding 18 33.3 
Managing hygiene 12 22.2 
Managing emotions 9 16.6 
Distressed 6 11.1 
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Appendix 2 
THE AUSTRALIAN RETT SYNDROME 
STUDY 
A questionnaire for parents 
Follow-up Study 
2004 
Thank you very much for taking part in this study. 
If you have any queries about the study in general or any aspect of this questionnaire, 
please do not hesitate to contact: 
Dr Helen Leonard (Medical Director} or Crystal Laurvick (Clinical Coordinator} 
Phone:08 9489 7790 Phone: 08 9489 7789 
Fax:08 9489 7700 
Mobile:0419 956 946 
Email:rett@ichr.uwa.edu.au 
Web address:www.ichr.uwa.edu.aujrettjaussierett 
FIRST TIME FAMILIES 
ID: ___ _ 
Section 11: Puberty 
We are interested in the physical changes that occur with age in girls and young women with 
ett syndrome. These sketches are widely used by clinicians to describe physical development. 
Please circle the picture below which best describes your daughter's breast development. 
,_,·, \ 
/ { \ 
( '\ ,J 
t I I 
\ ~~ 
Please circle the picture below which best describes your daughter's hip & pubic hair 
development. 
~ { . ( ' ' •' ··, ·' ~-,,~ T \ T ! r i I I i \ \ 
Is there anything about your daughter's sexual development that you would consider to 
be unusual or different than what you would expect for her age? 
D No 
D Yes, please describe in the following space 
··'= 
Has your daughter started having menstrual periods? 
D No, please go to Question 7. 
D Yes--> How hold was your daughter when she started her periods? 
'& Date I I or aged __ years & __ months 
···~ 
" 
Do you have or have you ever had any problems with your daughter's menstrual periods? s 
••••• D No 
••• 
.· .. D Yes, please feel free to make any comments about variations in 
functioning, symptoms, any aspect of your daughter relating to her 
menstrual cycle (eg. seizure activity) and about how you manage her 
... periods . 
; 
·. 
Is your daughter on any medication to manage her menstrual periods? 
·• 
D No 
D Yes, please provide details below: 
.... 
••• .· 
. 
Has she had any surgical procedures in relation to her periods or to any other 
gynaecological problem? 
D No 
D Yes, please complete the following table to the best of your ability. 
Hospital where surgery was done 
Date of procedure 
Type of surgery or age of the child at 
the time of surgery 
I 
·~ i ~. 
DowN SYNDROME NOW 
N EEDS O PINIONS W ISHES 
STUDY 
A questionnaire for parents 
Thank you for taking part in this study. 
If you have any queries about this questionnaire or the study in general, 
please do not hesitate to contact: 
Dr Helen Leonard (Medical Director) or 
Dhone:  
:ax:  
~o bile:  
~mail: hleonard@ichr.uwa.edu.au 
Crystal Laurvick (Project Coordinator) 
Phone: 08 9489 7789 
Email: crystall@ichr.uwa.edu.au 
Section 9: Puberty 
e are interested in your child's physical and emotional development during adolescence, and whether there 
is/was anything particularly unusual or difficult about this period. 
This section only needs to be filled out if your child is 12 YEARS OR OLDER. 
If your child is younger than 12 years, please go to Section 10. 
Has your child begun to display signs of puberty (eg., growth of pubic hair, breast budding, 
enlargement of testes)? 
0 No 
0 Yes - Please write the age of your child when you began to notice these changes: -~~ 
Is there anything about your child's sexual development that you would consider to be unusual 
or different from what you would expect for his/her age? 
' 
0 No 
0 Yes - please describe in the following space: 
Is there anything about your child's social and emotional development or behaviour during puberty 
that you would consider to be unusual or different from what you would expect for his/her age, or 
that you need/needed to handle in a different way because your child has Down syndrome? 
0 No 
0 Yes - please describe in the following space: 
Does your child use any methods of contraception? 
0 No 
0 Yes- please describe which method(s) and feel free to make any further comments: 
Please comment on any other issues arising during puberty. 
S' 
Questions 6-10 only need to be filled out if your child is FEMALE. 
If your child is male, please go to Section 10. 
Has your daughter started having menstrual periods? 
••• D No -please go to Section 10 
D Yes 
. 
. 
.. 
How old was your daughter when she started her periods? 
.. 
.. · Date I I or aged __ years & __ months 
...... 
Do you have or have you ever had any problems with your daughter's menstrual periods? 
••• D No 
D Yes, please feel free to make any comments about variations in functioning, 
symptoms, any aspect of your daughter relating to her menstrual cycle ( eg. 
seizure activity) and about how you manage her periods . 
... 
... 
i 
; 
'.t Is your daughter on any medication to manage her menstrual periods? 
D No 
s• D Yes, please provide details below: 
. 
.. · 
Has she had any surgical procedures in relation to her periods or to any other 
gynaecological problem? 
D No 
D Yes, please describe the procedures in the following table: 
Type of surgery Date of OR age at surgery 
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FL 33498; e-mail, ytaaidd@aol.com; phone, 561-482-0341. Contact her if you have any 
technical questions about manuscript preparation. 
Ethical Standards 
All investigations using human participants must have been approved by the human 
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Form 
All sections of the manuscript (including quotations, references, tables, and footnotes) 
should be double-spaced with at least a l-inch margin on all sides. The preferred length 
of manuscripts is 20-30 typed pages or less, but somewhat greater length may be 
accepted, depending on the complexity and importance ofthe research. Brief reports are 
generally 5 to 10 manuscript pages and contain a limited number of findings in 
comparison to research articles. 
Abbreviations and Terminology 
Abbreviations should be held to a minimum. The names of groups or experimental 
conditions should usually not be abbreviated. The full names of tests should be given 
when they are first mentioned, with the common shortened form in parentheses. 
When context makes it clear whether an author is referring to people with intellectual 
disabilities or when it is otherwise unnecessary to refer to intellectual level or diagnostic 
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References 
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tables may be deleted or combined into larger ones during the copyediting process. Lines 
should not be typed or inked within tables, and all columns should be provided with 
headings. AllenTrack accepts figures in JPEG, TIFF, GIF, BPS, PDF, or Postscript 
formats. Figure captions should be included in the manuscript text file, but other types of 
lettering may appear on the figures themselves. All such lettering should be of 
professional quality and large enough to withstand a reduction of approximately 50%. 
Release forms (signed, dated, and witnessed) must accompany photographs of human 
subjects. Care should be taken to conceal the identity of persons in such photographs. 
Authors must also secure permission to use any copyrighted tables or figures. 
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